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A B S T R A C T
Background
Skeletal muscle spasticity is a major physical complication resulting from traumatic brain injury (TBI), which can lead to muscle con-
tracture, joint stiffness, reduced range of movement, broken skin and pain. Treatments for spasticity include a range of pharmacological
and non-pharmacological interventions, often used in combination. Management of spasticity following TBI varies from other clinical
populations because of the added complexity of behavioural and cognitive issues associated with TBI.
Objectives
To assess the effects of interventions for managing skeletal muscle spasticity in people with TBI.
Search methods
In June 2017, we searched key databases including the Cochrane Injuries Group Specialised Register, CENTRAL, MEDLINE (Ovid),
Embase (Ovid) and others, in addition to clinical trials registries and the reference lists of included studies.
Selection criteria
We included randomised controlled trials (RCTs) and cross-over RCTs evaluating any intervention for the management of spasticity
in TBI. Only studies where at least 50% of participants had a TBI (or for whom separate data for participants with TBI were available)
were included. The primary outcomes were spasticity and adverse effects. Secondary outcome measures were classified according to
the World Health Organization International Classification of Functioning, Disability and Health including body functions (sensory,
pain, neuromusculoskeletal and movement-related functions) and activities and participation (general tasks and demands; mobility;
self-care; domestic life; major life areas; community, social and civic life).
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Data collection and analysis
We used standard methodological procedures expected by Cochrane. Data were synthesised narratively; meta-analysis was precluded
due to the paucity and heterogeneity of data.
Main results
We included nine studies in this review which involved 134 participants with TBI. Only five studies reported between-group differences,
yielding outcome data for 105 participants with TBI. These five studies assessed the effects of a range of pharmacological (baclofen, bo-
tulinum toxin A) and non-pharmacological (casting, physiotherapy, splints, tilt table standing and electrical stimulation) interventions,
often in combination. The studies which tested the effect of baclofen and tizanidine did not report their results adequately. Where
outcome data were available, spasticity and adverse events were reported, in addition to some secondary outcome measures.
Of the five studies with results, three were funded by governments, charities or health services and two were funded by a pharmaceutical
or medical technology company. The four studies without useable results were funded by pharmaceutical or medical technology
companies.
It was difficult to draw conclusions about the effectiveness of these interventions due to poor reporting, small study size and the fact that
participants with TBI were usually only a proportion of the overall total. Meta-analysis was not feasible due to the paucity of data and
heterogeneity of interventions and comparator groups. Some studies concluded that the intervention they tested had beneficial effects
on spasticity, and others found no difference between certain treatments. The most common adverse event was minor skin damage in
people who received casting. We believe it would be misleading to provide any further description of study results given the quality of
the evidence was very low for all outcomes.
Authors’ conclusions
The very low quality and limited amount of evidence about the management of spasticity in people with TBI means that we are
uncertain about the effectiveness or harms of these interventions. Well-designed and adequately powered studies using functional
outcome measures to test the interventions used in clinical practice are needed.
P L A I N L A N G U A G E S U M M A R Y
Treatments for spasticity (overactive muscle contractions) following brain injury
Review question
We reviewed the evidence about the effect of treatments (drug and non-drug) for spasticity following a brain injury caused by a blow
to the head (traumatic brain injury (TBI)).
Background
Many people with TBI experience muscle spasticity, when their muscles contract or tighten involuntarily. This can impact on a person’s
ability to carry out daily activities causing pain, stiffness and broken skin. There aremany treatments used tomanage spasticity, including
medicines, casting, splints and stretches. Often, these treatments are used in combination.
Study characteristics
We included nine studies in this review which involved 134 participants with TBI. Only five studies, including 105 people provided
usable results. These studies tested the effects of a range of treatments, including medicines (baclofen or botulinum toxin A), casting,
physiotherapy, splints, a table that moves people from the lying position to standing and electrical stimulation (where electrical impulses
are delivered to the muscles). Studies inadequately reporting results had tested the effect of medicines (baclofen or tizanidine).
Study funding sources
Of the five studies with results, three were funded by governments, charities or health services and two were funded by a drug
manufacturer and medical technology company. The other four studies without useable results were funded by drug manufacturer or
medical technology companies.
Key results
This evidence is current to June 2017.
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Interpreting the results of the studies was difficult because of a lack of information and concerns about the quality of the evidence.
For spasticity, some studies concluded that the treatment they tested made an improvement, and others found no difference between
treatments. The most common side effect was minor skin damage in people who received casting. We believe it would be misleading
to provide any further description of study results given the quality of the evidence was very low for all measurements.
Quality of the evidence
The quality of this evidence was very low; we only had five studies with results and none of the studies were large or comparable with
one another. We also had concerns about how they were conducted or analysed. Because of this, we cannot draw any firm conclusions
about the benefits and harms of different treatments for spasticity in people with TBI.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Baclofen compared with placebo for spasticity in people with traumatic brain injury
Patient or population: adults with traumatic brain injury with spast icity in their arms and legs
Settings: outpat ient rehabilitat ion clinic (US)
Intervention: intrathecal baclofen 50 µg (injected into the lumbar spine)
Comparison: saline placebo
Outcomes Results and conclusions No of participants
(studies)
Quality of the evidence
(GRADE)
Spasticity at up to 6 hours after treatment
(measured by the Ashworth Scale, 0-,with a
higher score indicat ing greater spast icity)
We are uncertain about the ef fect of






Adverse events We are uncertain about the ef fect of ba-






Sensory functions and pain No study measured this outcome.
Neuromusculoskeletal and movement- re-
lated functions up to 6 hours after treat-
ment
(Measured by spasm and deep tendon
ref lex scores, 0-5, with 0 being no ref lexes
and 5 being clonus, or repeated involuntary
muscle contract ions)
We are uncertain about the ef fect of ba-
clofen on neuromusculoskeletal and move-






General tasks and demands No study measured this outcome.
Mobility No study measured this outcome.












































































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1One study of baclofen reported an improvement in spast icity in the upper and lower limbs, compared to placebo, several
hours af ter the inject ions but it was unclear how meaningful this improvement was due to report ing of P values only
(Meythaler 1996).
2Three addit ional studies, with 35 part icipants, measured this outcome but had no useable results (Meythaler 1997; Meythaler
1999a; Meythaler 1999b).
3Downgraded four t imes due to risk of bias lim itat ions (this study provided insuf f icient information about random sequence
generat ion or allocat ion concealment), our concerns about indirectness of the Ashworth Score, an inability to assess
imprecision relat ing to an absence of conf idence intervals and a further downgrade for there only being one study for this
outcome and the likelihood of publicat ion bias in this area.
4No adverse events or changes in alertness level were observed in the baclofen or placebo group.
5Downgraded three t imes due to risk of bias lim itat ions (no study provided suf f icient information about random sequence
generat ion or allocat ion concealment), the fact that there was only one study for this outcome and the likelihood of publicat ion
bias in this area.
6One study reported improvement in upper and lower limb spasm and ref lexes compared to placebo several hours af ter
treatment but it was unclear how meaningful this improvement was due to report ing of P values only (Meythaler 1996).
7Downgraded four t imes due to risk of bias lim itat ions (no study provided suf f icient information about random sequence
generat ion or allocat ion concealment), an inability to assess imprecision relat ing to an absence of conf idence intervals, the












































































































B A C K G R O U N D
Traumatic brain injury (TBI) is the result of an external force to
the head, that can lead to permanent damage to the brain. There
are many causes of TBI including motor vehicle accidents, falls,
violent assaults or blast injuries (Maas 2008). In 2005, The US
Centre for Disease Control and Prevention estimated at least 3.17
million Americans, approximately 1.1% of the US population,
are living with long-term disability as a result of TBI (Summers
2009). In Europe, the incidence of TBI in studies published be-
tween 1983 and 2013 has been estimated to be between 47.3 to
849 per 100,000 population per year (Brazinova 2016). There are
limited data available for low- to middle-income countries. The
impact of TBI to a person can be far-reaching and may result in
ongoing physical, cognitive and behavioural issues (Khan 2003).
Skeletal muscle spasticity is one of the major physical complica-
tions following TBI (Brashear 2016).
Description of the condition
Spasticity is defined as an ongoing contraction of a muscle caused
by an increase in muscle tone and deep tendon reflexes that is
partly due to a reduction of the skeletal stretch reflex threshold
(Lance 1980). It is often described as muscle overactivity. Spastic-
ity occurs due to damage of upper motor neurons (UMN) of the
corticoreticular pathways in the brain cortex or internal capsule,
or damage to the UMNs in the reticulospinal or vestibulospinal
tracts in the spinal cord (Pandyan 2005). Spasticity may occur spo-
radically or continuously, for periods of short and long duration.
Spasticity tends to affect the antigravity muscle groups in the up-
per and lower limbs (Nair 2014). In the upper limbs, this can
commonly include the shoulder adductors, elbow, wrist and fin-
ger flexors, forearm pronators and thumb adductors. In the lower
limbs, spasticity often affects the hip adductors, knee flexors, ankle
plantarflexors and invertors, and big toe extensors (Nair 2014).
Spasticity can also affect muscles in the neck.
There are limited epidemiological data regarding the prevalence
of spasticity following TBI (Martin 2014; McGuire 2016). In one
systematic review of the epidemiology of lower limb spasticity,
Martin 2014 identified only one study (Singer 2004), conducted
in 105 people with TBI that found the prevalence of ankle spastic-
ity was 13%. Similarly, McGuire 2016 was only able to find one
study of spasticity prevalence following TBI (Wedekind 2005),
which was a study of 32 people with TBI, in which the prevalence
of spasticity (location unclear) was 32%.While both the definition
and measurement of spasticity is inconsistent, and often poorly
defined (Malhotra 2009), McGuire 2016 suggests that by extrap-
olating data from studies in other populations (including people
with stroke, spinal cord injury and multiple sclerosis), ’problem-
atic’ spasticity may occur in between 30% and 50% of people with
TBI.
Spasticity can lead to a range of musculoskeletal issues such as
muscle contracture, involuntary and uncontrollable shaking, joint
stiffness, reduced range of movement, broken skin and pain (Ada
2006a; Ada 2006b). The debilitating nature of the condition can
directly impact a person’s ability to carry out normal activities
of daily living (ADL), such as self-care and household tasks, and
is likely to lead to dependency on carers or family members for
assistance. Participation in daily life and opportunities for com-
munity integration can prove difficult and may ultimately impact
the person’s quality of life (Kwakkel 1999). Management of spas-
ticity in people with TBI varies from other clinical populations
primarily due to behavioural and cognitive issues that affect their
ability to participate in, or tolerate, treatment (e.g. their ability
to follow instructions, monitor use of a spastic limb or tolerate a
cast). These factors are likely to impact on whether or not a treat-
ment is effective in this population and limit the applicability of
findings from other populations where behavioural and cognitive
issues are not a primary concern (Manchester 1997; Wood 1999).
Furthermore, some studies have shown that mobility limitations
can be improved over time and that the presence, distribution and
severity of spasticity may not necessarily be the best determinant
in recovery and mobility outcomes (Williams 2015a; Williams
2015b).
The measurement of spasticity in clinical practice, and in research,
is challenging (Malhotra 2009). The most common scales to mea-
sure spasticity are the (Modified) Ashworth Scale (Pandyan 1999)
and the (Modified) Tardieu Scale (Haugh 2006). The (Modified)
Ashworth Scale is commonly used by clinicians as it is the eas-
ier scale to complete (Pandyan 1999), however it only measures
the resistance in a muscle, which may or may not be caused by
spasticity (Patrick 2006). This is in contrast to the (Modified)
Tardieu Scale which measures spasticity by the spasticity catch an-
gle as well as resistance in the muscle (Haugh 2006). The Tardieu
has also demonstrated greater test-retest and inter-rater reliability
compared with the Modified Ashworth Scale (Mehrholz 2005).
The (Modified) Tardieu includes a continuous and nominal (or
sometimes considered ordinal (Haugh 2006)) component, and the
(Modified) Ashworth is ordinal, but both are commonly treated
as continuous scales by trialists. While there does not appear to
be a clear consensus about the most appropriate way to analyse
these scales, we note that for another five-point ordinal scale used
in TBI (the Glasgow Outcome Scale (Jennett 1975)), a sliding di-
chotomy or proportional odds methodology is recommended for
analysis (Maas 2010).
Description of the intervention
Interventions for managing skeletal muscle spasticity can be
broadly categorised as either pharmacological or non-pharmaco-
logical. Examples of pharmacological interventions include ba-
clofen (Becker 1997), botulinum toxin A, clonidine, dantrolene
sodium, tizanidine and phenol injection (Meythaler 2001a; Yelnik
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2009). Examples of non-pharmacological interventions include
casting, splinting, stretching, strengthening, transcutaneous elec-
tric nerve stimulation (TENS) (Aydin 2005), Bobath treatment,
weight bearing gait training and seating. In practice, a combina-
tion of both pharmacological and non-pharmacological interven-
tions is used to manage spasticity. Interventions can be either focal
or systemic in their action. Focal interventions involve treatment
of one or two muscle groups whereas systemic interventions are
used to treat generalised spasticity.
How the intervention might work
Interventions used to manage spasticity all aim to reduce overac-
tivity within the muscle so that it can be lengthened (Esquenazi
2006).
Pharmacological interventions can act locally at the muscle or sys-
temically through the central nervous system. For example, bo-
tulinum toxin A and phenol are both injected locally at the site of
the spastic muscle whereas other interventions such as tizanidine
and clonidine are administered orally. Oral medications act sys-
temically and can induce unwanted adverse effects, such as drowsi-
ness. For those with severe spasticity in multiple areas, adverse ef-
fects associated with oral medications can sometimes outweigh the
potential benefits of reduced spasticity. An alternative approach,
as seen with baclofen, is to administer the treatment through a
pump into the space around the spinal cord, thus reducing the
impact of adverse effects whilst maintaining improved outcomes
for spasticity (Becker 1997).
Non-pharmacological interventions involve the use of physical
modalities such as stretching and strengthening to promote elon-
gation and control of spastic muscles, or external devices such as
casting or splinting to modify and maintain correct positioning
of a spastic muscle. Table 1 provides a summary of the range of
different interventions and their mode of action.
Table 1: Examples of the range of interventions to manage
spasticity
Pharmacological intervention Mode of action Non-pharmacological inter-
vention
Mode of action
Baclofen Administered orally or via in-
trathecal pump to limit the re-
lease of excitatory neurotrans-
mitters in the spinal cord
Casting Applied directly to the limb to
maintain the muscle in an ex-
tended position
Botulinum toxin A A neurotoxin injected directly
into the muscle to block the
release of the neurotransmitter
acetylcholine
Splinting Thermoplastic or fabric mate-
rial that is customised to pro-
vide support to a person’s limb
and maintain the limb in the
corrected position
Clonidine Administered orally or by trans-
dermal patch to act on the cen-
tral nervous system by reducing
the excitability of alpha motor
neurons
Seating Custom made seating for peo-
ple to provide maximal support
and reduce the impact of spas-
ticity
Dantrolene sodium Administered orally to reduce
the excitation-contraction cou-
pling within the skeletal mus-
cle and decrease the strength of
muscle contraction
Stretching Promotes elongation of a mus-
cle for varying lengths of time
causing viscous deformation
changes
Phenol Injected into specific nerves to
induce neurolysis to perma-




placed on the skin over a spastic
muscle to reduce pain
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(Continued)
Tizanidine Administered orally to act on
the central nervous system and
reduce the excitability of alpha
motor neurons
Surgery Surgical techniques primarily
aim to alter the structure of a
muscle or nerve or relocate a
tendon to change its function
Why it is important to do this review
A range of interventions are currently used tomanage skeletal mus-
cle spasticity for people with TBI. Clinical management often in-
volves a combination of pharmacological and non-pharmacologi-
cal interventions. Management of spasticity following TBI varies
from other clinical populations because of the added complexity
of behavioural and cognitive issues associated with TBI. Further-
more, the current management for spasticity in other conditions
may not be applicable to TBI as a result of global UMN damage
that can occur such as axonal shearing, haemorrhage and hypoxia.
A comprehensive systematic review of interventions assessed in the
TBI population is needed to identify those likely to have the great-
est impact for managing spasticity as well as determining whether
the severity of TBI or the timing of an intervention is relevant to
the outcome.
Reviews of interventions for spasticity in people with TBI are fo-
cused solely on the effect of one intervention (botulinum toxin A),
and include people with spasticity due to other conditions, pre-
dominantly stroke (Baker 2015; Dashtipour 2016; Dong 2017).
None of these reviews allow conclusions to be drawn specific to
people with TBI. Systematic reviews that consider the effects of a
broader range of interventions for managing spasticity have done
so in populations other thanTBI such as stroke (Taricco 2000) and
spinal cord injury (Demetrios 2013; Hsieh 2012). To our knowl-
edge, there are no systematic reviews that consider all potential
interventions used to manage skeletal muscle spasticity specifically
for people with TBI.
O B J E C T I V E S
To assess the effects of interventions for managing skeletal muscle
spasticity in people with TBI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCT). Cross-over trials
were included as long as the sequence of treatments was randomly
allocated.
Types of participants
We included people with TBI of any age (i.e. children and adults),
who had skeletal muscle spasticity experienced at any time after
injury. We made a post-hoc decision to include only studies that
either:
• included at least 50% of people with TBI amongst their
participants;
• provided disaggregated data for participants with TBI if the
proportion of participants within the trial was less than 50%.
This decision was made in response to the identification of a large
number of studies with mixed populations (e.g. stroke and TBI)
that were found during screening to ensure the evidence would be
applicable to people with TBI.
Types of interventions
We included studies that compared any of the following: pharma-
cological or non-pharmacological intervention (or a combination
of both) or placebo/no treatment.
Types of outcome measures
Primary outcomes
• Spasticity, measured using common tools such as the
Tardieu or Modified Tardieu Scale (Haugh 2006), or the
Ashworth Scale or Modified Ashworth (Pandyan 1999).
• Adverse events.
As a post-hoc decision, we took Tardieu or Modified Tardieu,
in preference to the (Modified) Ashworth Scale, in the instance
that an included study used both these measures. This decision
was made given the (Modified) Ashworth poorly differentiates be-
tween spasticity and contracture (Patrick 2006), and as the Tardieu
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is considered to have greater test-retest and inter-rater reliability
compared with the Modified Ashworth Scale (Mehrholz 2005).
Secondary outcomes
A range of secondary outcomes were included, classified according
to the World Health Organization International Classification of
Functioning, Disability and Health (WHO 2010) using the fol-
lowing domains.
Body functions
• Sensory functions and pain (e.g. pain intensity).
• Neuromusculoskeletal and movement-related functions
(e.g. goniometric measurement).
Activities and participation
• General tasks and demands (e.g. Canadian Occupational
Performance Measure (Law 2000)).
• Mobility (e.g. gait and balance measures).
• Self-care (e.g. Functional Independence Measure (Keith
1987)).
• Domestic life (e.g. Goal Attainment Scale (Kiresuk 1994)).
• Major life areas (e.g. Functional Assessment Measure (Hall
1993)).
• Community, social and civic life (e.g. quality of life
measures).
Information size calculation
In line with Cochrane Injuries policy, we undertook a post-hoc
information size calculation, to determine the sample size required
in a meta-analysis for the primary outcome, spasticity. Determin-
ing the parameters for this calculation was difficult, as the most
commonly used measure of spasticity (the Ashworth or Modified
Ashworth Scale) was not necessarily the most clinically meaning-
ful, or appropriate (Haugh 2006), and it is also an ordinal scale
that is frequently treated as continuous. Considering we could be
combining more than one spasticity scale, we applied the ’rule of
thumb’ for determining a ’small’ difference between two groups as
a standardised mean difference (SMD) of 0.2 standard deviations
(Guyatt 2011). Assuming 90% power at the 5% significance level,
this means that we require 526 participants in both the interven-
tion and control groups within a meta-analysis to be able to detect
a difference between groups, if such a difference exists.
Search methods for identification of studies
To reduce publication and retrieval bias, we did not restrict our
search by language, date or publication status.
Electronic searches
The information in this review is current to June 2017. Studies
were identified through searches run in 2013, 2016 and 2017.
In November 2013, we searched the following databases:
• Cochrane Injuries Group specialised register (1 November
2013);
• the Cochrane Library (2013, Issue 10);
• Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid OLDMEDLINE(R) (1946 to 1 November 2013);
• Embase Classic + Embase (OvidSP) (1947 to 1 November
2013);
• PubMed (www.ncbi.nlm.nih.gov/pubmed/) (1 November
2013);
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to 01 November 2013);
• ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S) (1990 to 1 November 2013);
• CINAHL Plus (1939 to 1 November 2013);
• PsycINFO (1806 to November 2013);
• PEDro (Physiotherapy Evidence Database) (1929 to
November 2013);
• OTSeeker (Occupational Therapy Systematic Evaluation of
Evidence) www.otseeker.com (1955 to November 2013);
• Database of Abstracts of Reviews of Effects (DARE)
(November 2013).
InMay 2016, the Cochrane Injuries Group Information Specialist
developed and ran a new search. This was because of changes in
the author team that meant we were unable to locate the exact
search strategies used in the original search (beyond the MED-
LINE strategy). The database list was reduced and included:
• Cochrane Injuries Group Specialised Register (16 May
2016);
• MEDLINE (OvidSP) (16 May 2016);
• Embase Classic and Embase (OvidSP) (16 May 2016).
The search strategies for the 2016 search are listed in Appendix 1.
The Cochrane Injuries Information Specialist conducted a final
prepublication search in June 2017. Given these searches were
revised again by the Cochrane Injuries Information Specialist, we
have listed the databases below. Some of the original databases were
not searched in 2017 as the databases did not yield any unique
studies in earlier searches.
We searched the following databases in June 2017 (and dedupli-
cated against earlier yields):
• Cochrane Injuries Group Specialised Register (SR-INJ) (22
June 2017);
• the Cochrane Library (2017, Issue 6);
• Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid OLDMEDLINE(R) (2013 to 22 June 2017);
• Ovid Embase (1974 to 22 June 2017);
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• PubMed (not MEDLINE) (www.ncbi.nlm.nih.gov/
pubmed/) (22 June 2017);
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (1970 to 22 June 2017);
• ISI Web of Science: Conference Proceedings Citation
Index-Science (CPCI-S) (1990 to 22 June 2017);
• ClinicalTrials.gov (www.clinicaltrials.gov) (22 June 2017);
• WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/) (22 June 2017).
These search strategies are listed in Appendix 2 so they can be used
in future updates.
Searching other resources
We screened the reference lists of all included articles and relevant
reviews to identify additional studies for inclusion in the review.
Data collection and analysis
Selection of studies
Two review authors (KP, MC or AS) independently screened ci-
tations on abstract and title against the selection criteria. We ob-
tained potentially eligible citations in full text and repeated the
process. The two review authors discussed disagreements regard-
ing study eligibility until consensus was reached or consulted a
third review author for a final decision. For trials with mixed pop-
ulations, we contacted study authors to obtain data or clarification
(or both) to inform inclusion and exclusion decisions.
Data extraction and management
Two review authors (KP, MC or AS) independently extracted the
data from included studies using a standardised data collection
form, that was first piloted by two authors. One review author
(KP) made a final check. We contacted the primary authors of
included studies to provide data and clarification where adequate
data were not reported.
Assessment of risk of bias in included studies
Two review authors (KP, MC or AS) independently assessed risk
of bias of the included studies using the Cochrane ’Risk of bias’
tool (Higgins 2011). We assessed sequence generation; allocation
concealment; blinding of participants, personnel and outcome as-
sessors; incomplete outcome data; selective outcome reporting;
baseline imbalances and other bias issues. Additional domains for
cross-over trials included appropriate study design and adequate
washout period. Studies were rated as low, high or unclear risk of
bias for each domain, according to the criteria used in theCochrane
’Risk of bias’ tool.
Measures of treatment effect
We extracted raw data (means and standard deviations for contin-
uous outcomes and number of events for binary outcomes) for the
primary and secondary outcomes. Where these were not provided,
we extracted additional data such as sum scores and P values. We
extracted postintervention scores over change scores.
Where possible, we calculated summary data as risk ratio (RR)
with 95% confidence intervals (CI) (dichotomous outcomes) and
mean difference (MD) with 95% CI (continuous data). Had we
been able to pool continuous outcomes where the outcome was
measured using different tools across studies, we would have used
standardised mean difference (SMD) with 95% CI. We analysed
data in Review Manager 5 (RevMan 2011).
Unit of analysis issues
We sought to explore unit of analysis issues in the cross-over trials,
but were unable to do so due to insufficient reporting.
Dealing with missing data
We contacted the primary authors of potentially eligible studies
to provide data and clarification, where required. While several
authors provided additional information to inform eligibility de-
cisions, we did not receive any additional outcome data (some
authors did not respond to our contact and others no longer had
access to study data). We describe missing data and dropouts/at-
trition for each included study in the ’Risk of bias’ table, and dis-
cussed the extent to which the missing data could have altered the
results and conclusions of the review.
Assessment of heterogeneity
We considered the clinical heterogeneity of studies, but statistical
assessment of heterogeneity was not possible due to the absence
of meta-analysis. If meta-analysis is possible in future updates, we
will consider the magnitude and direction of effect and make a
visual inspection of forest plots to assess the degree of overlap of
CIs across separate studies and statistical heterogeneity quantified
using the I2 statistic (Higgins 2011).
Assessment of reporting biases
Due to insufficient studies, formal assessment of reporting bias (via
funnel plots) could not be carried out. In future updates, if there
are more than 10 studies assessing the same outcome(s), we will
construct a funnel plot to investigate small study effects (Higgins
2011).
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Data synthesis
Wehad planned to pool outcome data for studies that were consid-
ered sufficiently similar. The diversity of interventions and com-
parator groups as well as paucity of data available meant that a
pooled analysis was not possible, therefore the results for each
study are presented narratively. We grouped and assessed studies
based on the type of intervention (pharmacological or non-phar-
macological or a combination of both) and the comparison group
(no treatment, placebo studies or an alternative intervention).
We assessed and reported the quality of the body of evidence con-
tributing each outcome using the GRADE criteria (Schünemann
2011). These five criteria are: risk of bias, inconsistency, impreci-
sion, indirectness and publication bias. Two review authors (AS,
MC) independently assessed the quality of the evidence using the
GRADE approach (Ryan 2016; Schünemann 2011).
Subgroup analysis and investigation of heterogeneity
We were unable to conduct planned subgroup analyses due to the
lack of data. Should there be sufficient data in future updates, we
will undertake subgroup analyses to investigate the effect of:
• timing of intervention post injury (i.e. early: within two
years, versus late: at least two years’ postinjury);
• severity of TBI defined by the Glasgow Coma Scale
(Teasdale 1974);
• severity of spasticity as defined by the Ashworth Scale for
muscle spasticity;
• single intervention versus combined interventions;
• mixed population studies versus studies with TBI
participants only;
• adults versus children.
Sensitivity analysis
We were unable to conduct the planned sensitivity analysis due
to the lack of available data. Should there be sufficient studies in
future updates, we will investigate the effect of removing studies
with inadequate or unclear allocation concealment from meta-
analyses. This domain was selected as the allocation sequence can
be concealed in all RCTs (unlike some domains, e.g. like blinding),
and there is empirical evidence demonstrating the increased risk
of selection bias that can be introduced by unconcealed allocation
in studies with more subjective outcomes (such as spasticity and
others assessed in this review) (Wood 2008).
’Summary of findings’ tables
We made a post-hoc decision to prepare ’Summary of findings’
tables to present the meta-analysed or narrative results along with
the GRADE ratings of our main outcomes. These outcomes were
selected on the basis of their clinical importance, rather than the
study results. The outcomes included in the ’Summary of findings’
table are: spasticity, adverse events, sensory functions and pain,
neuromusculoskeletal and movement-related functions, general
tasks and demands, mobility and self-care.
R E S U L T S
Description of studies
Results of the search
Combining the yields of all searches up to June 2017, we identified
1743 citations after deduplication, excluding 1527 of these on
title and abstract (see Figure 1). This left 216 citations assessed
in full text, of which 201 were excluded (see Figure 1; Excluded
studies; Characteristics of excluded studies table and Table 1 for
more information and reasons).
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Figure 1. Study flow diagram for searches up until June 2017. TBA: traumatic brain injury.
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Of the remaining 15 studies that were considered for inclu-
sion, we require further information about five studies (see the
Characteristics of studies awaiting classification table) and one
study is ongoing (see the Characteristics of ongoing studies table).
The anticipated end date for the ongoing study investigating the
combined effect of serial casting and botulinum toxin A on ankle
contractures is September 2018 (ACTRN12615000821594).
We therefore included nine completed trials (Gracies 2015;
Leung 2014; Meythaler 1996; Meythaler 1997; Meythaler 1999a;




We included nine studies involving data from 385 par-
ticipants (134 with TBI) (Gracies 2015; Leung 2014;
Meythaler 1996; Meythaler 1997; Meythaler 1999a; Meythaler
1999b; NCT00287157; Pittaccio 2013; Verplancke 2005; see
Characteristics of included studies table). Of these, three were par-
allel group RCTs, with two (Leung 2014) or three comparator
groups (Gracies 2015; Verplancke 2005). Six were randomised
cross-over trials comparing treatment with placebo or stan-
dard care (Meythaler 1996; Meythaler 1997; Meythaler 1999a;
Meythaler 1999b; NCT00287157; Pittaccio 2013).
Of the nine trials, three did not identify between-group dif-
ferences in outcome data, neither did they report sufficient in-
formation about the results to allow us to calculate these dif-
ferences (Meythaler 1997; Meythaler 1999a; Meythaler 1999b).
Results from one trial remain unpublished and unavailable
(NCT00287157). As such, only the data from five studies (com-
bined 350 participants, of whom 105 had TBI) contributed out-
come data to the results of this review (Gracies 2015; Leung 2014;
Meythaler 1996; Pittaccio 2013; Verplancke 2005).
Number of participants
Within each study, the number of participants (TBI and non-
TBI) ranged from six (Meythaler 1999a) to 243 (Gracies 2015).
Most of these trials included mixed populations (TBI and non-
TBI). Two studies solely recruited people with TBI (51 combined
participants) (Meythaler 1999b; Leung 2014), while Gracies 2015
provided disaggregated data for their subgroup of 23 participants
with TBI (in the form of a conference abstract; O’Dell 2015). In
the remaining six studies with mixed populations, the number of
participants with TBI ranged from three (Meythaler 1999a) to 20
(Verplancke 2005), and the proportions of participants with TBI
ranged from 50% (Meythaler 1999a) to 91% (Meythaler 1996).
Setting
All the trials were conducted in high-income settings, including
the US (four trials), Australia (one trial), the UK (one trial), Italy
(one trial) and Israel (one trial). One trial drew data from sites
in nine high-income countries (Belgium, Czech Republic, France,
Hungary, Italy, Poland, Russia, Slovakia, USA) (Gracies 2015).
Participants were recruited from either tertiary care (outpatient or
inpatient, or both) rehabilitation clinics or acute general hospitals.
Of the five studies with results, three were funded by govern-
ments, charities or health services (Meythaler 1996; Leung 2014;
Pittaccio 2013), and two were funded by pharmaceutical/medi-
cal technology companies (Gracies 2015; Verplancke 2005). The
four studies without useable results were funded by pharmaceu-
tical/medical technology companies (Meythaler 1997; Meythaler
1999a; Meythaler 1999b; NCT00287157).
Participants
Age and sex
With the exception of Gracies 2015, data for age and gender were
not reported separately for TBI participants when they formed a
proportion of ’mixed’ populations. For this reason, the following
information relates to the whole sample (including non-TBI par-
ticipants) within trials except for Gracies 2015, along with Leung
2014 and Meythaler 1999b, which were the only trials in which
all participants had a diagnosis of TBI.
Seven studies included adults, with a mean (or median) age
of participants between 24 years (Meythaler 1996) and 41.5
years (Verplancke 2005). Two studies included children (
NCT00287157; Pittaccio 2013); only Pittaccio 2013 reported
the mean age of participants, being 7.75 years. Where reported,
all studies include more males than females, ranging from 60%
(Meythaler 1999a) to 92% (Meythaler 1997).
Body part treated
Four studies treated spasticity anywhere in the lower limbs, but
also treated upper limb spasticity, if present (Meythaler 1996;
Meythaler 1997; Meythaler 1999a; Meythaler 1999b). Two stud-
ies treated spasticity in the calf muscles (gastrocnemius, or gastroc-
nemius and soleus) (Leung 2014; Verplancke 2005), whileGracies
2015 treated spasticity in the upper limbs only (specifically elbow
flexors, wrist flexors or finger flexors) and Pittaccio 2013 treated
spasticity in the ankle or elbow. One study did not report the lo-
cation of the spasticity (NCT00287157).
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Interventions and comparators
The nine studies tested a varied range of pharmacological and
non-pharmacological interventions. Pharmacological interven-
tions that were tested against saline/placebo included intrathe-
cal baclofen (Meythaler 1996; Meythaler 1997; Meythaler 1999a;
Meythaler 1999b) and tizanidine (NCT00287157). Two addi-
tional, three-armed trials tested botulinum toxin A; Gracies 2015
tested two different doses of botulinum toxin A against placebo,
and Verplancke 2005 assessed botulinum toxin A plus casting
against placebo plus casting and against physiotherapy.
Non-pharmacological interventions and comparisons tested in-
clude casting and physiotherapy (Verplancke 2005), pseudoelastic
orthosis versus a traditional splint (Pittaccio 2013), and a combi-
nation of tilt table standing, electrical stimulation and ankle splint-
ing versus tilt table standing alone (Leung 2014).
More details are provided about the interventions tested, grouped
under different comparisons.
Baclofen versus placebo
Meythaler 1996 examined the effect of intrathecal baclofen for
spastic hypertonia in the lower limbs. Eleven participants were
allocated to receive a bolus intrathecal injection of either normal
saline or baclofen 50 µg. Cross-over of participants occurred 48
hours after the initial administration. This study was in two parts:
use of a bolus dose and then those participants with an adequate re-
sponse were progressed to implantation of an intrathecal baclofen
pump. This would be considered the usual method for evaluation
for implantation of a baclofen pump.
The three other baclofen studies (Meythaler 1997; Meythaler
1999a; Meythaler 1999b) also assessed intrathecal baclofen infu-
sion at the same dosage (50 µg), but provided no useable results.
Botulinum toxin A (with or without casting) versus placebo
(with or without casting)
Gracies 2015 assessed the effect of botulinum toxin A versus
placebo for upper limb spasticity in 23 participants with TBI. In
the initial treatment cycle, 14 participants received either abobo-
tulinumtoxinA (500 U or 1000 U) and nine received placebo. The
mode of administration was intramuscular injection. However, for
participants with TBI, results were given in a binary method (only
intervention versus placebo, without regard to dosage of abobo-
tulinumtoxinA).
Verplancke 2005 compared the effects of three different interven-
tions in 25 adults with lower limb spasticity, which we split into
three, two-arm comparisons. The comparison included here is bo-
tulinum toxin A injections plus casting (12 participants) (200 U/
leg) versus placebo plus casting (12 participants) (total of 4 mL
saline injections).
Physiotherapy versus placebo plus casting or botulinum
toxin A plus casting
The remaining comparisons for Verplancke 2005 were physiother-
apy alone (11 participants) compared with casting plus botulinum
toxin A injections (12 participants) (200 U/leg) or casting with
placebo (12 participants) (total of 4 mL saline injections) in adults
with lower limb spasticity.
Tizanidine versus placebo
NCT00287157 assessed the effect of tizanidine versus placebo on
spasticity, cognition and daily function. The results were unpub-
lished and no data were available.
Pseudoelastic orthosis versus traditional splint
In Pittaccio 2013, 25 children with elbow or ankle spasticity wore
a spring-loaded orthosis comprised of two parts that could rotate
relative to one another around a commonaxis thatwas individually
customised andworn for onemonth. A traditional static splint was
fitted and worn for one month. These treatments were delivered
in a randomised cross-over manner.
Tilt table standing, electrical stimulation and ankle splinting
versus tilt table standing alone
Leung 2014 (36 participants) evaluated a multi-modal treatment
including 30 minutes of tilt table standing with electrical stimu-
lation to the ankle dorsiflexors five times a week, with 12 hours
per day of ankle splinting, at least five days a week. This was com-
pared to the control group, who received 30 minutes of tilt table
standing, three times a week. The total programme duration for
intervention and control groups was six weeks.
Outcomes
For the five studies in which outcome data were provided, results
were available for the primary outcomes of spasticity (assessed us-
ing the Tardieu Scale (Gracies 2015; Leung 2014), the Ashworth
Scale (Meythaler 1996), or the Modified Ashworth Scale (Gracies
2015; Pittaccio 2013; Verplancke 2005)) and adverse events. All
authors treated their measures of spasticity as continuous and nu-
merical data providedwere often sparse. Secondary outcomesmea-
sured included neuromusculoskeletal andmovement-related func-
tions (i.e. deep tendon reflexes, ankle range of movement), mo-
bility, major life areas and community, social and civic life. The
remaining secondary outcomes of interest to this review (sensory
function and pain, general tasks and demands, self-care and do-
mestic life) were not measured. Detailed information about the
domains and scores used for these outcomes and the timing of
their measurement in the studies is described in Table 2 and Table
3.
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Excluded studies
In total, we excluded 169 studies on reading the full text, for rea-
sons including no TBI participants (96 studies), less than 50%
of participants had TBI and results not presented separately (27
studies), no evaluation of treatments for spasticity (28 studies)
or ineligible study design (e.g. review article; 18 references; see
Characteristics of excluded studies for a list of 58 key studies ex-
cluded on full text).
Given the relatively large number of studies (27) that were ex-
cluded as less than 50% of study participants had a TBI (and
the data for these participants were not presented separately), we
provided more information in Table 1. Across these studies, there
were 1000 participants, of whom 142 (14%) had TBI. The per-
centage of people within each study who had TBI ranged from
2% to 47%.
Risk of bias in included studies
The risk of bias for all included studies varied as detailed in the
Characteristics of included studies table, and presented in Figure
2 and Figure 3. Many items were scored as ’unclear’ due to poor
reporting.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies. Nine studies are included in this review.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study (note: only Meythaler 1996 and Verplancke 2005 contributed outcome data to the review).
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Allocation
Of the nine included studies, investigators involved in only two
studies clearly reported the methods of both randomisation and
allocation concealment, and these were assessed at low risk of bias
for these domains (Gracies 2015; Leung 2014). None of the other
study authors provided details of either randomisation or alloca-
tion concealment methods, making it difficult to determine any
associated risks of bias. Seven studies were thus rated at ’unclear’
risk of bias for both these domains.
Blinding
Five studies reported adequate blinding of participants andperson-
nel (Gracies 2015; Meythaler 1996; Meythaler 1997; Meythaler
1999a;Meythaler 1999b). In three studies neither participants nor
personnel could be blinded due to the obvious differences between
interventions and controls (e.g. serial casting, different orthoses/
splints), leading to ratings of high risk (Leung 2014; Pittaccio
2013; Verplancke 2005). The registry entry for NCT00287157
provided insufficient information and as such this study was rated
as unclear.
Four studies explicitly reported that outcome assessors were
blinded (Gracies 2015; Leung 2014; Meythaler 1996; Verplancke
2005). It is noteworthy that these were amongst the only stud-
ies with outcome data included in the review. In four studies, it
was unclear if outcome assessors were blinded (Meythaler 1997;
Meythaler 1999a; Meythaler 1999b; NCT00287157), and in one
study outcome assessors could not be blinded, hence it was rated
at high risk (Pittaccio 2013).
Incomplete outcome data
Six studies reported no losses to follow-up and were at low risk
of attrition bias (Gracies 2015; Meythaler 1996; Meythaler 1997;
Meythaler 1999a; Meythaler 1999b; Pittaccio 2013). Verplancke
2005 reported four withdrawals and three deaths; however, their
final measurements for these participants were those taken before
withdrawal from the study (rated as unclear as they did not report
which group they were randomised to). Leung 2014 reported four
losses to follow-up, with reasons that were unrelated to the trial;
however, they were not balanced between groups. Both studies
were rated as unclear risk of bias. The rating for NCT00287157
was ’unclear’ due to lack of information.
Selective reporting
One study was at low risk of bias given the availability of a pub-
lished protocol, which aligned with the subsequently published
trial (Leung 2014). Three studies were at unclear risk of bias for se-
lective reporting, as there were no published protocols (Meythaler
1996; Meythaler 1997; Meythaler 1999b). One study was also
rated at unclear risk of bias as, while it did have a published proto-
col for the main study, the TBI subset outcome data for different
doses of the active intervention were conflated and results were
given in the formof percentages only (Gracies 2015). Three studies
did not reference published protocols (neither could we identify
any) and were at high risk due to additional incomplete report-
ing of their results (Meythaler 1999a; Pittaccio 2013; Verplancke
2005). NCT00287157 was at high risk of bias as the authors ad-
vised that the trial data were “negative,” and was subsequently not
published.
Other potential sources of bias
Baseline imbalances
With regards to baseline imbalances, five studies were at low
risk of bias (Meythaler 1996; Meythaler 1997; Meythaler 1999a;
Meythaler 1999b; Pittaccio 2013). Four studies were judged as un-
clear for this domain (Gracies 2015; Leung 2014;NCT00287157;
Verplancke 2005). NCT00287157 was judged as unclear due to
lack of information, whereas the other two studies described their
groups as being ’similar’ at baseline, but subsequently outlined
some differences between the groups.
Appropriate study design
For the six cross-over trials, five used an appropriate study design
(Meythaler 1996; Meythaler 1997; Meythaler 1999a; Meythaler
1999b; Pittaccio 2013). The remaining trial was at unclear risk of
bias.
Adequate washout period
Three cross-over trials provided enough information to be judged
as having an adequate washout period (low risk of bias) (Meythaler
1996; Meythaler 1997; Meythaler 1999a). Investigators in one
trial judged it unethical to have a washout period (Pittaccio 2013).
Statistical tests were conducted and presented demonstrating that
sequential order did not affect treatment response, so this trial was
also assessed as having a low risk of bias. The remaining two cross-
over trials were at unclear risk of bias for this domain (Meythaler
1999b; NCT00287157).
Other bias
With regards to ’other bias’, three studies (Meythaler 1997;
Meythaler 1999a; Meythaler 1999b) were at high risk of bias due
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to unit of analysis issues (outcomes were analysed by looking at
upper versus lower extremities, rather than considering each mus-
cle separately; scores for muscle tone, spasms and reflexes were
averaged for the upper or lower extremities in each participant).
Four studies were at unclear risk of bias due to insufficient in-
formation (NCT00287157); the close role of the funder (a phar-
maceutical company) in the study design, conduct and analysis
(Gracies 2015); the inclusion of a participant who did not meet
the study inclusion criteria (Pittaccio 2013); and marked differ-
ences in the number of tilt table sessions between the intevention
and control groups (Leung 2014). We did not identify any other
bias concerns with the remaining two studies (Meythaler 1996;
Verplancke 2005).
Effects of interventions
See: Summary of findings for the main comparison Baclofen
compared with placebo for spasticity in people with traumatic
brain injury; Summary of findings 2 Botulinum toxin A (with
and without casting) compared with placebo (with and without
casting) for spasticity in people with traumatic brain injury;
Summary of findings 3 Pseudoelastic orthosis versus traditional
(static) splint for spasticity in people with traumatic brain injury
Baclofen versus placebo
One study with usable results compared baclofen versus placebo
(Meythaler 1996). (Three other studies compared baclofen to
placebo but had no useable results; Meythaler 1997; Meythaler
1999a; Meythaler 1999b.) A summary of the results of the main
outcomes for this comparison is provided in Summary of findings
for the main comparison.
Spasticity
Meythaler 1996 (11 participants, all included in the analysis) re-
ported between-group differences in both the lower and upper ex-
tremity Ashworth scores using P values, but with no effect sizes or
CIs. It was unclear which statistical tests were used. As the study
authors did not report any raw data for the placebo group results,
we could do no further analysis. The authors reported a ’signif-
icant’ improvement with baclofen compared to placebo at four
hours (P = 0.0084) and six hours (P = 0.0163) after administra-
tion. Baclofen was also associated with ’significant’ improvements
compared to placebo for upper extremity Ashworth score (P =
0.0097) at four hours after administration, however this effect was
not sustained at six hours (P value not reported).
The quality of the evidence on the effect of baclofen versus placebo
for spasticity was very low (downgraded four times). This was due
to risk of bias limitations (no study provided sufficient information
about the random sequence generationor allocation concealment),
our concerns about indirectness of the Ashworth score, an inability
to assess imprecision relating to an absence of CIs and a further
downgrade for there only being a single study for this outcome and
the likelihood of publication bias in this area. Considered together
with the fact that we could not judge how clinically relevant the
improvements were in this study, we were very uncertain about the
effect of baclofen on spasticity and unable to draw any conclusions.
Adverse events
There were no adverse events or changes in alertness level in the
baclofen or placebo groups (see Table 4).
The quality of the evidence on the effect of baclofen versus placebo
for spasticity was very low (downgraded three times). This was due
to the same risk of bias concerns as for spasticity and that there was
only one study for this outcome and the likelihood of publication
bias in this area. As such, wewere very uncertain about the effect of
baclofen on adverse events compared to placebo and were unable
to draw any conclusions.
Neuromusculoskeletal and movement-related functions
Meythaler 1996 (11 participants, all included in the analysis) re-
ported that lower extremity spasm scores were significantly im-
proved for baclofen versus placebo at four hours (P = 0.0073) and
six hours (P = 0.0049) as were lower extremity reflex scores (P =
0.0086 at four hours and P = 0.0085 at six hours). This effect was
also observed for the upper extremity spasm scores (P = 0.0117)
and reflex scores (P = 0.0272) at four hours after administration
when baclofen was compared to placebo. This effect was not sus-
tained at six hours (P value not reported).
The quality of this evidence was very low (downgraded four times,
for all the reasons outlined for spasticity) and we are very uncertain
about the effect of baclofen on neuromusculoskeletal and move-
ment-related functions.
Outcomes not measured
The study did not report: sensory functions and pain; general tasks
and demands; mobility; self-care; domestic life; major life areas;
and community, social and civic life.
Botulinum toxin A (with and without casting) versus
placebo (with and without casting)
Two studies compared botulinum toxin A (with and without cast-
ing) versus placebo (with and without casting) (Gracies 2015;
Verplancke 2005). A summary of the results of themain outcomes
for this comparison is provided in Summary of findings 2.
Spasticity
Gracies 2015 (23 participants) report that four weeks after injec-
tion, “with abobotulinumtoxinA, the angle of catch (XV3 of the
TS) improved in finger (+35 degree), elbow (+22 degree) and wrist
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(+12 degree) flexors, resulting in a gain in active muscle exten-
sion of at least 5 degrees active range of movement.” No further
outcome data were provided, and they did not comment on the
’statistical significance’ of this result. We note that the dosage that
produced this result (500 U or 1000 U) was unclear as data from
both groups (total 14 participants) were pooled against placebo
(nine participants).
Verplancke 2005 (35 participants) compared three different in-
terventions, which we report as three two-arm comparisons (the
authors analysed pre- and post-treatment differences in the Mod-
ified Ashworth Scale within groups, but not between groups). As
such, we calculated the between-group difference in spasticity (as
measured by the Modified Ashworth Scale at 12 weeks) for bo-
tulinum toxin A plus casting versus placebo plus casting as MD
0.30 points (95% CI -0.87 to 1.47; Analysis 1.1).
The quality of the evidence for this outcome was very low (down-
graded four times). This was due to risk of bias concerns for both
studies (downgraded twice, because either insufficient informa-
tion about random sequence generation and allocation conceal-
ment, in one study, and potential selective outcome reporting in
both studies), indirectness (one study measured spasticity using
theModified Ashworth Scale) and a high likelihood of publication
bias in this area. As such, we were very uncertain about the effect
of botulinum toxin A with and without casting versus placebo
with and without casting on spasticity and were unable to draw
any conclusions.
Adverse events
In Gracies 2015, the authors reported that “7 of 23 patients ex-
perienced a treatment emergent AE [adverse event]” and that of
these, “none were unexpected.” There was no further detail given
in the short conference proceeding reporting results for the TBI
population. In the main trial publication (of which people with
TBI only made up 9%), the most common treatment-related ad-
verse event was ’mild muscle weakness’ and investigators reported
that all adverse events were mild or moderate only (see Table 4).
In Verplancke 2005, botulinum toxin A was to be well tolerated,
with only one participant with ’flu-like’ symptoms (i.e. shivering,
sweating and fever). For the casting group, 50% developed mi-
nor skin damage (66.6% of those was partial thickness skin loss
involving epidermis). Finally, in the botulinum toxin A plus cast-
ing group, 41.7% of participants developed skin damage (60%
of those was discolouration, but skin still intact). Overall, 90.9%
of those resolved spontaneously or with therapeutic dressing (see
Table 4).
The quality of the evidence for adverse events was very low (down-
graded three times). This was due to risk of bias concerns for both
studies (downgraded twice, because in one study there was insuffi-
cient information about random sequence generation and alloca-
tion concealment, and in both studies the adverse events data were
reporting in percentages only) and a high likelihood of publication
bias in this area. As such, wewere very uncertain about the effect of
botulinum toxin A with and without casting versus placebo with
and without casting on adverse events and were unable to draw
any conclusions.
Neuromusculoskeletal and movement-related functions
Verplancke 2005 reported between-group differences in ankle dor-
siflexion, and found no differences between groups in a one-way
ANOVA (placebo plus casting versus botulinum toxin A plus cast-
ing: P = 0.11). However, they did not report any summary statis-
tics for this, or any baseline scores.
The quality of the evidence for neuromusculoskeletal and move-
ment-related functions was very low for the reasons outlined for
spasticity (downgraded four times). As such, we were very un-
certain about the effect of botulinum toxin A with and without
casting versus placebo with and without casting on neuromus-
culoskeletal and movement-related functions and were unable to
draw any conclusions.
Major life areas
Both Gracies 2015 and Verplancke 2005 measured outcomes we
classified under major life area outcomes. Gracies 2015 reported
an “improvement in subjective function for the treated group (>1
grade decrease from baseline for the principal target of treatment
on the Disability Assessment Scale (DAS)): 71% versus 22% for
placebo.” They did not provide this in absolute numbers, or com-
ment on the ’statistical significance’ of the result. Verplancke 2005
reported Glasgow Outcome Scale (GOS) and Glasgow Coma
Scale scores at follow-up in each of the three groups, but reported
mean values and did not report between-group differences.
The quality of the evidence formajor life areas was very low (down-
graded three times). This was due to risk of bias concerns for both
studies (downgraded twice, because in one study there was insuf-
ficient information about random sequence generation and allo-
cation concealment, and in both studies the outcome data were
inappropriately analysed or reported in percentages only) and a
high likelihood of publication bias in this area. As such, we were
uncertain about the effect of botulinum toxin A with and without
casting versus placebo with and without casting on major life areas
and were unable to draw any conclusions.
Community, social and civic life
In Gracies 2015, the authors reported two quality of life measures
(subscores of the 36-item Short Form Health (SF-36) and the
EuroQol (EQ-5D); however, these outcomes were not reported
separately for the subset of participants with TBI.
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Outcomes not measured
The studies did not report: sensory functions and pain, general
tasks and demands, mobility, self-care and domestic life.
Physiotherapy versus placebo plus casting or
botulinum toxin A plus casting
One study compared physiotherapy versus placebo plus casting or
botulinum toxin A plus casting (Verplancke 2005).
Spasticity
Verplancke 2005 compared three treatment groups: physiother-
apy, placebo plus casting and botulinum toxin A plus casting. The
authors analysed pre- and post-treatment differences in the Mod-
ified Ashworth Scale within but not between groups. As such,
we calculated the following between-group differences in spastic-
ity (as measured by the Modified Ashworth Scale at 12 weeks):
botulinum toxin A plus casting versus physiotherapy (MD -0.50
points, 95% CI -1.82 to 0.82; Analysis 2.1) and placebo plus
casting versus physiotherapy (MD -0.80 points, 95% CI -2.00 to
0.40; Analysis 3.1).
The quality of the evidence for physiotherapy compared to casting
or botulinum toxin A plus casting on spasticity was very low.
This was due to concerns about risk of bias related to insufficient
information provided about allocation concealment and blinding,
concerns about indirectness of the Modified Ashworth Scale, an
inability to assess imprecision relating to an absence of CIs and a
further downgrade for there only being one study for this outcome
and the likelihood of publication bias in this area. As such, we are
very uncertain about the effect of casting versus botulinum toxin
A plus casting versus physiotherapy on spasticity and were unable
to draw any conclusions.
Adverse events
Verplancke 2005 withdrew two participants due to an adverse
event (seeTable 4).Onewas due todeep vein thrombosis (DVT) in
the physiotherapy group and one was due to soft tissue contracture
at the subtalar joint in the placebo plus casting group. For the
adverse events related to botulinum toxin A, see the adverse events
listed under the comparison above, botulinum toxin A with and
without casting versus placebo with and without casting.
The quality of the evidence for physiotherapy versus placebo plus
casting or botulinum toxin A plus casting on adverse events was
very low. This was due to concerns about risk of bias related to
insufficient information provided about allocation concealment
and blinding, and a further downgrade for there only being one
study for this outcome and the likelihood of publication bias in
this area. As such,wewere very uncertain about the effect of casting
versus botulinum toxin A plus casting versus physiotherapy on
adverse events and were unable to draw any conclusions.
Neuromusculoskeletal and movement-related functions
Verplancke 2005 reported between-group differences in ankle dor-
siflexion and found no differences between groups in a one-way
ANOVA (physiotherapy versus placebo plus casting: P value not
significant, physiotherapy versus botulinum toxin A plus casting:
P = 0.07). However, they did not report any summary statistics
for this, or any baseline scores.
The quality of the evidence for physiotherapy versus placebo
plus casting or botulinum toxin A plus casting on neuromuscular
and movement-related outcomes was very low (downgraded three
times). This was due to concerns about risk of bias (related to
insufficient information provided about randomisation schedule
generation and allocation concealment, a lack of blinding and se-
lective outcome reporting), an inability to assess imprecision relat-
ing to an absence of data and a further downgrade for there only
being one study for this outcome and the likelihood of publication
bias in this area. As such, we were very uncertain about the effect
of casting versus botulinum toxin A plus casting on neuromuscu-
lar and movement-related functions and were unable to draw any
conclusions.
Major life areas (e.g. Functional Assessment Measure)
Verplancke 2005 reported GOS and GCS scores at follow-up in
each of the three groups, but reported mean values and did not
report between-group differences.
Outcomes not measured
The study did not report: sensory functions and pain; general tasks
and demands; mobility; self-care; domestic life; and community,
social and civic life.
Pseudoelastic orthosis versus traditional (static) splint
One study compared pseudoelastic orthosis versus traditional
(static) splint in children (Pittaccio 2013). A summary of the re-
sults of the main outcomes for this comparison is provided in
Summary of findings 3.
Spasticity
Pittaccio 2013 measured spasticity using the Ashworth Scale, but
reporting for clinical outcomes in this paperwas scant. The authors
providednooutcomedata for spasticity but stated that, “therewere
no significant differences on means by paired 2-tailed Student’s t
test” between the two types of splint.
The quality of the evidence was very low. The rating was down-
graded four times due to risk of bias limitations (the study provided
no information about sequence generation and allocation conceal-
ment; blinding was impossible for participants or personnel and
not reported for outcome assessors; selective outcome reporting
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bias was high); our concerns about indirectness of the Ashworth
score and indirectness due to 36% of participants not having TBI
and one participant was of dubious eligibility; an inability to assess
imprecision relating to an absence of meaningful outcome data
(no numerical data were provided for spasticity; investigators re-
ported only that there were no significant differences), there was
only one study for this comparison/outcome and publication bias
was possible in this area. As such, we were very uncertain about the
effect of pseudoelastic orthoses versus a traditional (static) splint
on spasticity and were unable to draw any conclusions.
Adverse events
Pittaccio 2013 reported that both participants and families ’reacted
positively’ to the pseudoelastic orthoses, which were described as
well-tolerated for several hours a day, and never caused problems
familiar to those using more traditional devices including a skin
rash, haematomas or pain (see Table 4). None of the pseudoelas-
tic orthoses had to be modified to improve comfort, while some
adjustments were required for approximately 30% of traditional
splints, in order to reduce skin rash, haematomas and oedema. Tol-
erability was assessed by questionnaire. The investigators conceded
that true knowledge of comfort/discomfort experienced by chil-
dren in the trial was impossible to assess as most participants were
unable to communicate; nevertheless, questionnaire data were re-
ported to be encouraging and on average, the pseudoelastic devices
were tolerated 40% longer than traditional splints.
The quality of the evidence was very low (downgraded four times).
The quality was downgraded due to risk of bias limitations (this
study provided insufficient information about sequence genera-
tion and allocation concealment, blinding was impossible for par-
ticipants and personnel and not reported for outcome assessors,
and selective reporting bias was high). We had concerns about in-
directness given that 36% of participants did not have TBI and
one participant was of dubious eligibility. Furthermore, there was
only one study for this comparison/outcome and publication bias
was possible in this area. As such, we were very uncertain about the
effect of pseudoelastic orthoses versus a traditional (static) splint
on adverse events and were unable to draw any conclusions.
Neuromusculoskeletal and movement-related functions
Pittaccio 2013 reported results for range of motion as non-sig-
nificant (“no significant differences on means by paired 2-tailed
Student’s t tests”) and no further numerical data were given.
The quality of the evidence was very low. The quality of the ev-
idence was downgraded five times due to risk of bias limitations
(this study provided insufficient information about sequence gen-
eration and allocation concealment, blinding was impossible for
participants and personnel and not reported for outcome assessors,
and selective reporting bias was high). We had concerns about in-
directness due to 36% of participants not having TBI and one par-
ticipant was of dubious eligibility; our inability to assess impreci-
sion given thatmeans and standard deviations were only presented
within a small box and whiskers plot, and a further downgrade for
there only being one study for this comparison/outcome and the
likelihood of publication bias in this area. As such, we were very
uncertain about the effect of pseudoelastic orthoses versus a tra-
ditional (static) splint on neuromusculoskeletal and movement-
related functions and were unable to draw any conclusions.
Outcomes not measured
The study did not report: sensory functions and pain; general tasks
and demands; mobility; self-care; domestic life; major life areas;
and community, social and civic life.
Tilt table standing, electrical stimulation and ankle
splinting versus tilt table standing alone
One study compared tilt table standing, electrical stimulation and
ankle splinting versus tilt table standing alone (Leung 2014).
Spasticity
Leung 2014 measured spasticity at six weeks (end of programme)
and 10 weeks (end of trial) using the 5-point ’reaction to passive
stretch at high speed’ component of the Tardieu Scale. Leung 2014
treated this as a continuous scale and reported the difference be-
tween groups using change scores, which we plotted using postin-
tervention scores only (see Analysis 4.1). This resulted in an MD
of -1.00 points (95% CI -1.66 to -0.34) at week six (in favour
of tilt table standing, electrical stimulation and ankle splinting)
and an MD of 1.00 (95% CI 0.31 to 1.69) at week 10 (in favour
of tilt table standing alone). This is broadly consistent with the
conclusions of the authors that “there was a small mean reduction
of 1 point in spasticity at Week 6 (95% CI 0.1 to 1.8) in favour of
the experimental group, but this effect disappeared at Week 10.”
The quality of the evidence for tilt table standing, electrical stimu-
lation and ankle splinting versus tilt table standing alone on spas-
ticity was very low (downgraded three times). This was due to
concerns about indirectness (downgraded once for potentially in-
appropriate analysis of the Tardieu Scale as a continuous measure),
imprecision (downgraded once as there was only one small study
for this outcome) and the likelihood of publication bias in this
area (downgraded once). As such, we were very uncertain about
the effect of tilt table standing, electrical stimulation and ankle
splinting versus tilt table standing alone on spasticity and were
unable to draw any conclusions.
Adverse events
While Leung 2014 did not explicitly measure adverse events, they
provided a description of a number of factors that influenced sev-
eral participants’ adherence to tilt table standing, including faint-
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ing, fatigue and storming (when someone with a head injury re-
sponds to a sensation with a tonic posture or sympathetic re-
sponse). Additionally, two participants’ adherence to splinting was
affected by “skin problems” and “poor tolerance.”
Neuromusculoskeletal and movement-related functions
Leung 2014 measured passive ankle dorsiflexion at 12 Nm at six
weeks (end of programme) and 10 weeks (end of trial). Dorsiflex-
ion was measured relative to a neutral ankle position (0 degrees),
with a positive score indicating dorsiflexion (the desired direction
of movement) and a negative score indicating plantarflexion. They
explored the differential effects using change scores, but we recal-
culated this using postintervention scores (see Analysis 4.2). This
yielded an MD of -2.00 degrees (95% CI -7.19 to 3.19) at six
weeks and an MD of 1.00 degree (95% CI -3.31 to 5.31) at 10
weeks.
The quality of the evidence for tilt table standing, electrical stim-
ulation and ankle splinting versus tilt table standing alone on neu-
romuscular and movement-related functions was very low (down-
graded three times). This was due to imprecision (downgraded
once) related to the CI including both a meaningful benefit and
harm, using Leung 2014’s prespecified ’minimum worthwhile
treatment effect’ of 5 degrees, there was only one study for this
outcome (downgraded once) and the likelihood of publication
bias in this area (downgraded once). As such, we were very uncer-
tain about the effect of tilt table standing, electrical stimulation
and ankle splinting versus tilt table standing alone on neuromus-
culoskeletal and movement-related functions and were unable to
draw any conclusions.
Mobility
Leung 2014 measured mobility using walking speed (in metres/
second) at six weeks (end of programme) and 10 weeks (end
of trial). They assessed between-group differences using change
scores, which we recalculated using postintervention scores (see
Analysis 4.3). This yielded a MD of -0.10 m/second (95% CI -
0.43 to 0.23) at six weeks and 0.00 (95% CI -0.38 to 0.38) at 10
weeks.
The quality of the evidence for tilt table standing, electrical stim-
ulation and ankle splinting versus tilt table standing alone on mo-
bility was very low. The quality of the evidence was downgraded
four times due to risk of bias concerns (participants and personnel
could not be blinded and there were some imbalances between
groups in the length of time since injury and the number of tilt
table sessions received), for imprecision (single study and the CI
included a potential benefit and harm) and the likelihood of pub-
lication bias in this area. As such, we were uncertain about the
effect of tilt table standing, electrical stimulation and ankle splint-
ing versus tilt table standing alone on mobility and were unable
to draw any conclusions.
The study did not report: sensory functions and pain; general
tasks and demands; self-care; domestic life; major life areas; and
community, social and civic life.
Tizanidine versus placebo
One study compared tizanidine versus placebo (NCT00287157)
in children. However, we have no information regarding partic-
ipants and no information about the effect of tizanidine versus
placebo on spasticity or any other outcomes as the results of this
study are unavailable and unpublished.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Botulinum toxin A (with and without casting) compared with placebo (with and without casting) for spasticity in people with traumatic brain injury
Patient or population: adults with traumatic brain injury with spast icity in their arms (1 study) or calves (1 study)
Settings: rehabilitat ion/ neurology clinics or acute general hospital, in Europe or the UK
Intervention: botulinum toxin A × 1 dose (500/ 1000 U) or botulinum toxin A × 1 dose of 200 U + serial cast ing
Comparison: placebo (± cast ing)
Outcomes Results and conclusions No of participants
(studies)
Quality of the evidence
(GRADE)
Spasticity at 4-12 weeks (measured by
both Modif ied Ashworth Scale, 0-5, at 12
weeks and Tardieu Scale, 0-5, at 4 weeks)
We are uncertain about the ef fect of bo-
tulinum toxin A (± cast ing) vs placebo (±





Adverse events We are uncertain about the ef fect of bo-
tulinum toxin A (± cast ing) vs placebo (±





Sensory functions and pain No study measured this outcome.
Neuromusculoskeletal and movement- re-
lated functions at 12 weeks (measured by
ankle dorsif lexion)
We are uncertain about the ef fect of bo-
tulinum toxin A (± cast ing) vs placebo (±





General tasks and demands No study measured this outcome.
Mobility No study measured this outcome.
Self- care No study measured this outcome.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.












































































































1Gracies 2015 reported that ‘‘with abobotulinumtoxinA, the angle of catch (XV3 of the Tardieu Scale) improved in f inger (+35
degree), elbow (+22 degree) and wrist (+12 degree) f lexors’’ but no further outcome data were provided. For Verplancke
2005, we calculated the between-group dif ference in spast icity (as measured by the Modif ied Ashworth Scale) as mean
dif ference 0.30 (95% conf idence interval -0.87 to 1.47).
2Included studies: Gracies 2015; Verplancke 2005.
3Downgraded four t imes due to: risk of bias concerns for both studies (downgraded twice, because either insuf f icient
information about random sequence generat ion and allocat ion concealment, in one study, and potent ial select ive outcome
report ing in both studies), indirectness (one study included mixed traumatic brain injury and stroke populat ions, and measured
spast icity using the Modif ied Ashworth Scale) and a high likelihood of publicat ion bias in this area.
4In the main trial of Gracies 2015 (in which the traumatic brain injury populat ion was a part (9.5%)) the most common
botulinum toxin A-related adverse event was ’m ild muscle weakness’ and invest igators reported that all adverse events were
mild or moderate only. In Verplancke 2005, botulinum toxin A was reported to be well tolerated, with only one part icipant
with ’f lu-like’ symptoms (i.e. shivering, sweating and fever). In groups who received cast ing (either alone, or in addit ion
to botulinum toxin A), 41% to 50% developed ’m inor’ skin damage. Overall, 90.9% of those resolved spontaneously or with
therapeut ic dressing.
5Downgraded three t imes due to: risk of bias concerns for both studies (downgraded twice, because in one study there was
insuf f icient information about random sequence generat ion and allocat ion concealment, and in both studies the adverse
events data was report ing in percentages only) and a high likelihood of publicat ion bias in this area.
6Verplancke 2005 reported between-group dif ferences in ankle dorsif lexion, f inding no dif ferences between groups in a one-
way ANOVA (cast ing + placebo versus cast ing + botulinum toxin A: P = 0.11). However, they did not report any summary
stat ist ics for this, or any baseline scores.
7Downgraded four t imes due to: risk of bias concerns for both studies (downgraded twice, because either insuf f icient
information about random sequence generat ion and allocat ion concealment, in one study, and potent ial select ive outcome
report ing in both studies), indirectness (one study included mixed traumatic brain injury and stroke populat ions) and a high













































































































Pseudoelastic orthosis versus traditional (static) splint for spasticity in people with traumatic brain injury
Patient or population: children/ young people aged 4-18 years with traumatic brain injury and with ’m ild to severe spast ic tetraparesis’ (weakness) in all limbs
Settings: Ist ituro Eugenio Media (Italy)
Intervention: reposit ioning splints equipped with part icipant-specif ic pseudoelast ic hinges
Comparison: t radit ional splints with f ixed angle braces
Outcomes Results and conclusions No of participants
(studies)
Quality of the evidence
(GRADE)
Spasticity at up to 6 hours after treatment
(measured by the Modif ied Ashworth
Scale, 0-4, with a higher score indicat ing
greater spast icity)
We are uncertain about the ef fect of pseu-
doelast ic splints compared with tradit ional





Adverse events We are uncertain about the ef fect of pseu-
doelast ic splints compared with tradit ional





Sensory functions and pain The included study did not report this outcome.
Neuromusculoskeletal and movement- re-
lated functions post treatment
(measured by range of movement)
We are uncertain about the ef fect of pseu-
doelast ic splints compared with tradit ional





General tasks and demands The included study did not report this outcome.
Mobility The included study did not report this outcome.
Self- care The included study did not report this outcome.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.












































































































1One study comparing novel pseudoelast ic orthoses to tradit ional f ixed angle splints reported no improvement in spast icity
in the upper and lower limbs, over a period of one month of intervent ion. and that results of the two steps were not
signif icant ly dif f erent (Pit taccio 2013).
2Downgraded four t imes due to risk of bias lim itat ions (study provided no information about sequence generat ion and
allocat ion concealment; blinding was impossible for part icipants or personnel and not reported for outcome assessors;
select ive outcome report ing bias was high); our concerns about indirectness of the Ashworth Score and indirectness due
to 36% of part icipants not having traumatic brain injury and one part icipant was of dubious eligibility; an inability to assess
imprecision relat ing to an absence of meaningful outcome data (no numerical data were provided for spast icity; invest igators
reported only that there were no signif icant dif f erences), and there was only one study for this comparison/ outcome and that
publicat ion bias was possible in this area.
3No adverse events were reported for pseudoelast ic orthoses neither did any require adjustments af ter f it t ing. Adjustments
were required for 30% of tradit ional splints to reduce skin rash, haematomas and oedema.
4Downgraded four t imes due to risk of bias lim itat ions (study provided insuf f icient information about sequence generat ion and
allocat ion concealment, blinding was impossible for part icipants and personnel and not reported for outcome assessors, and
select ive report ing bias was high). We had concerns about indirectness given that 36% of part icipants did not have traumatic
brain injury and one part icipant was of dubious eligibility. Furthermore, there was only one study for this comparison/ outcome
and publicat ion bias was possible in this area.
5One study reported no improvement in range of movement in the upper and lower limbs, over a period of one month of
intervent ion (Pit taccio 2013).
6Downgraded f ive t imes due to risk of bias lim itat ions (this study provided insuf f icient information about sequence generat ion
and allocat ion concealment, blinding was impossible for part icipants and personnel and not reported for outcome assessors,
and select ive report ing bias was high). We had concerns about indirectness due to 36% of part icipants not having traumatic
brain injury and one part icipant was of dubious eligibility; our inability to assess imprecision given that means and standard
deviat ions were only presented within a small box and whiskers plot, and a further downgrade for there only being one study













































































































D I S C U S S I O N
Summary of main results
We found nine RCTs, including 385 participants (of whom 134
had TBI), that assessed the effect of a wide range of pharmacologi-
cal and non-pharmacological treatments for spasticity as a result of
TBI. Only five of these studies reported results in sufficient detail
to allow synthesis in the review. As such, we included data from
studies with 350 participants (105 of whom had TBI) in which
baclofen, botulinum toxin A, casting, physiotherapy, splints, tilt
table standing and electrical stimulation were tested, either alone
or in combination.
Given such heterogeneity of interventions, trials for any given in-
tervention were few, and sample sizes were small. Added to this,
reporting of methods and results for trials was patchy, we had con-
cerns about indirectness given the number of studies in this review
with mixed populations, and publication bias given the known
(and potentially unknown) unpublished studies in this area. These
factors combined to mean there was a paucity of evidence about
the effect of interventions for themanagement of spasticity in peo-
ple with TBI. The quality of the evidence for all outcomes was
very low.
In the interests of completeness, we provided a rudimentary sum-
mary of the results for the primary outcomes of spasticity and ad-
verse events. Results were mixed for spasticity, but we cautioned
against drawing conclusion given the very low quality evidence.
For pharmacological interventions, baclofen had a greater effect
than placebo after six hours of treatment in the lower limbs but
not upper limbs (Meythaler 1996), and botulinum toxin A had
a greater effect than placebo at four weeks in the upper limbs
(Gracies 2015), but when combined with casting it had no greater
effect than casting alone in the lower limbs (Verplancke 2005). For
non-pharmacological studies, physiotherapy compared with cast-
ing in the lower limbs (Verplancke 2005), and novel pseudoelas-
tic splints with traditional splints at the ankle or elbow (Pittaccio
2013), demonstrated no differences between treatments.
For adverse events, the quality of the evidence was similarly very
low, but the results were a little more consistent. For pharmaco-
logical treatments, there were no adverse events reported in the
baclofen study (Meythaler 1996), or the group which received
botulinum toxin A in Verplancke 2005, but 7/23 participants
in the botulinum toxin A study by Gracies 2015 experienced a
“treatment emergent adverse event” (no further information pro-
vided). Many of the non-pharmacological treatments were asso-
ciated tolerability/adherence issues, including traditional splints
(Leung 2014; Pittaccio 2013) and tilt table standing (Verplancke
2005). In Verplancke 2005, between 41.7% and 50% of par-
ticipants who received casting developed minor skin damage, of
which, 90% resolved spontaneously. In Verplancke 2005, two
more serious adverse events developed in the physiotherapy group
(DVT) and the casting plus placebo group (joint contracture).
Due to the very low quality of evidence, we were uncertain about
the effects of any of these interventions for managing spasticity.
Overall completeness and applicability of
evidence
This review indicated that the evidence for existing interventions
for managing spasticity in TBI is limited. Given the paucity of
well-designed and reported trials, the applicability of this review
to the TBI population was limited as there were many factors that
needed to be considered which none of the studies addressed.
Clinicians can find themanagement of TBI challenging due to the
varying extent of the UMN damage causing spasticity affecting
many muscles and joints, trunk, limbs, head and neck leading to
complex physical disabilities and often coexisting cognitive and
behavioural impairments. These confounding factors can impact
on spasticity management as people with TBI may have a lower
tolerance for treatments, as well as an inability to monitor or par-
ticipate in the learning and practice required for rehabilitation.
Consideration for a greater research base to be developed in this
area is extremely important.
There are varying levels of evidence for the management of spas-
ticity in other neurological populations (Ade-Hall 2000; Amatya
2013; Duarte 2016; Demetrios 2013; Lindsay 2013; RCP 2009;
Shakespeare 2003; Taricco 2000). There is an assumption made
that the effects of pharmacological and non-pharmacological in-
terventions in other conditions (e.g. multiple sclerosis, stroke) are
the same for TBI. While at an impairment level the outcome may
potentially be comparable, there can be a difference at a functional
level. There is little evidence for the effect of these interventions
at a functional level (Francis 2004).
Quality of the evidence
The quality of the evidence for all outcomes was very low due
to risk of bias concerns (a combination of poor reporting and
poor conduct), indirectness related to mixed populations or the
outcome measures used (or both), imprecision and the likelihood
of publication/reporting biases in this area. We did not formally
downgrade the quality of the evidence for the analysis approach
taken in studies that measured spasticity (where all the authors
treated the ordinal scales as continuous) given the lack of consensus
about how best to analyse these data, but this may introduce a
further flaw in the interpretation.
Potential biases in the review process
The decision to limit inclusion of studies with a mixed clinical
population to those with greater than 50% of participants with
TBI had a major impact on the number of included studies in the
review. Had we reduced or removed the threshold, we could have
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increased the number of included studies by a further 27. Had we
increased the threshold to 100% (similar to the approach taken
in one TBI trial overview (Bragge 2016)) we would have reduced
the number of included studies to three. As such, the level of the
threshold used in the reviewmay have affected the results and con-
clusions. This threshold was set during the screening stages of the
review (i.e. before extraction of results data) and was determined
using clinical judgement.
Agreements and disagreements with other
studies or reviews
As far as we are aware, this is the only systematic review evalu-
ating any intervention for skeletal muscle spasticity, specifically
in people with TBI. Three non-Cochrane systematic reviews of
RCTs have each investigated the efficacy of botulinum toxin A for
spasticity (due to TBI and other causes) in the upper limbs (Dong
2017), lower limbs (Dashtipour 2016), and upper and lower limbs
(Baker 2015). Each review included amajority of studies in people
with stroke, but all included some studies with mixed stroke and
TBI populations. Dashtipour 2016 was the only review to include
any study (Gracies 2015) that was common to our review. These
reviews concluded that there was favourable evidence to support
the use of botulinum toxin A in the upper limb (both Baker 2015
and Dong 2017 found improvements in global benefit or “ease of
care” measures) and either an absence of evidence (Baker 2015)
or ’the beginnings of an evidence base’ showing spasticity reduc-
tions (Dashtipour 2016) in the lower limb. Given the included
studies in each of these reviews included predominantly people
with stroke, we would question the applicability of these results
to people with TBI. One other non-Cochrane systematic review
looked at the use of casting in people with brain injury, the major-
ity of whom had TBI (Mortenson 2003). Only five out of the 13
included studies measured spasticity as an outcome and reported
improvement to some extent following casting. However, it was
noted by the author that the quality of this evidence was low and
that none of these studies used a true randomised design.
There are several Cochrane Reviews that investigated a broader
range of treatments for spasticity in other conditions such
as stroke (Demetrios 2013), multiple sclerosis (Amatya 2013;
Shakespeare 2003), amyotrophic lateral sclerosis/motor neuron
disease (Ashworth 2012), cerebral palsy (Ade-Hall 2000; Hoare
2010), and spinal cord injury (Taricco 2000). Interventions ranged
from multidisciplinary rehabilitation following botulinum toxin
A (and other intramuscular treatment), pharmacological (e.g. bo-
tulinum toxin A, baclofen, tizanidine) and non-pharmacological
interventions (e.g. physical activity), or a combination of interven-
tions. It is notable that with the exception of one review (Hoare
2010), all reviews reported low or insufficient evidence for any of
these interventions as a result of heterogeneity, high risk of bias
and lack of information. Hoare 2010 found strong evidence to
support botulinum toxin A as an adjunct to occupational therapy
in managing upper limb spasticity in children with cerebral palsy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review identified a number of studies in which the authors
evaluated the effectiveness of spasticity treatment in traumatic
brain injury (TBI); however, there is insufficient evidence from
clinical trials to guide clinical practice.
Implications for research
There is an urgent need for more high quality, adequately powered
trials in this area; the lack of TBI participants in studies is of
great concern. In addition, there is a need for further evaluation of
the assessment tools to ensure that the outcomes for people with
TBI and spasticity are reliable. Any future studies should include
specific functional measures which focus on goal attainment for
individual patients.
Data need to be made available from studies which remain un-
published.
Outcome assessment of spasticity treatment is complicated. Two
assessment scales measuring the impairment caused by spasticity
are generally used; the Modified Ashworth Scale (Pandyan 1999)
and the Modified Tardieu Scale (Haugh 2006). Four studies in-
cluded within this review used the (Modified) Ashworth Scale.
This scale is considered to measure resistance to passive move-
ment not spasticity, as it does not evaluate a muscle’s response to
movement at speed (Allison 1995; Pandyan 2005). Spasticity is an
indication of abnormal neural mechanisms causing a velocity-de-
pendent increase in tonic stretch reflexes (Lance 1980). Therefore,
by this definition, it will only be seen when a muscle is moved at
speed. Where spasticity may be present in a muscle, the muscle
may have altered mechanical properties that have developed over
time causing a resistance to passive movement. It is these proper-
ties which can affect the quantification of spasticity by the Mod-
ified Ashworth Scale (Morris 2002). In comparison, the Modi-
fied Tardieu Scale (Haugh 2006; Mehrholz 2005), used by two
studies included within this review (Gracies 2015; Leung 2014),
is considered by many to be more appropriate measure with sim-
ilar characteristics as the Modified Ashworth Scale; however, the
scale requires that movement be carried out at two different speeds
recording a ’catch angle.’ It is this component of the scale that is
more appropriate for measuring spasticity (Haugh 2006; Morris
2002). However, it is also notable that there are reliability issues
with both measures; the Modified Tardieu Scale has very good
test-retest reliability, but both have reduced inter-rater reliability
(Fleuren 2010; Haugh 2006; Mehrholz 2005; Morris 2002).
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Any spasticity intervention needs to address specific functional
limitations for a person such as drinking from a glass or fastening
a button (Francis 2004; Mayer 2008; Parke 1989; Pierson 1996).
An individualised goal directed functional assessment combined
with an impairment assessment is recommended to evaluate the
effect of an intervention for people with a TBI. Global measures
of function are only valid where global treatments such as baclofen
are used. It is important that specific measures are identified for
specific functional deficits so that any intervention can be assessed
by the functional gains made by a person. Potential harms also
need to be considered for treatments with proven effectiveness.
Spasticity interventions can be costly and painful for a person.
Spasticity can be blamed for weakness, contracture and loss of
function, and if not clearly identified interventions for spasticity
can be used inappropriately, causing further discomfort for no
measurable benefit, and awaste of time andmoney.With respect to
impairments such as pain and broken skin, impairment measures
alone can indicate an effective outcome.
It has been acknowledged that spasticity intervention should oc-
cur within the context of a rehabilitation team, and little evidence
exists to demonstrate how or where this should occur (Demetrios
2013; Giovannelli 2007; Olver 2010; RCP 2009). It is recom-
mended that “botox injection must be part of a rehabilitation
program involving post-injection exercise, muscle stretch and/or
splinting to achieve an optimal clinical effect” (RCP 2009, p.vii).
The implementation of ’botox’ clinics which have a multidisci-
plinary approach to allow for assessment, treatment and review
can mirror some of the rehabilitation processes that occur in a
rehabilitation programme. However, when people have returned
to living in the community these processes may not occur so ef-
fectively due to lack of access or funding. It is not only the com-
plexity of TBI with its associated behaviours and cognitive issues
that complicate managing this population, but also where a per-
son lives, their access to services and the type of support they have
available to live their life.
A moderate to severe TBI can lead to long-term disability impact-
ing on ADL and quality of life. Impairments such as spasticity can
reduce independence, and cause pain and dysfunction in a person’s
life. It is important to identify interventions for this population
which will maximise the functional gains required for a person
with TBI to achieve their goals. We need to assess these outcomes
utilising reliable and valid assessment scales and this needs to oc-
cur within management programmes which have structure and
support for clinicians and people with TBI alike.
A C K N OW L E D G E M E N T S
The authors would like to thank Cochrane Injuries Group Man-
aging Editor Helen Wakeford and Co-ordinating Editor Emma
Sydenham for their helpful advice and assistance, along with Jane
Dennis (Editor) for her help incorporating two studies and devel-
oping ’Summary of findings’ tables, and Jo Weldon for serving as
a consumer referee. We acknowledge Anne Parkhill for consulta-
tion and advice regarding the original search strategies, and would
like to thank Deirdre Beecher and Sarah Dawson (Cochrane In-
juries Information Specialists) for revising and rerunning subse-
quent searches. Finally, we thank current and former Cochrane
Australia staff (Kelly Allen, JoMcKenzie, Miranda Cumpston and
Simon Turner) for their valuable methodological and statistical
input.
R E F E R E N C E S
References to studies included in this review
Gracies 2015 {published data only}
Gracies JM, Brashear A, Jech R, McAllister P, Banach M,
Valkovic P, et al. Safety and efficacy of abobotulinumtoxinA
for hemiparesis in adults with upper limb spasticity after
stroke or traumatic brain injury: a double-blind randomised
controlled trial. Lancet Neurology 2015;14:992–1001.
∗ O’Dell MW, Walker HW, Edgley SR, Gracies JM, Gul F,
Wimmer M, et al. AbobotulinumtoxinA (Dysport®) in the
treatment of adult patients with upper limb spasticity due
to traumatic brain injury. PM & R : the Journal of Injury,
Function, and Rehabilitation 2015;7:S103.
Leung 2014 {published data only}
Leung J, Harvey LA, Moseley AM, Whiteside B, Simpson
M, Stroud K. Standing with electrical stimulation and
splinting is no better than standing alone for management of
ankle plantarflexion contractures in people with traumatic
brain injury: a randomised trial. Journal of Physiotherapy
2014;60:201–8.
Meythaler 1996 {published data only}
Meythaler JM, DeVivo MJ, Hadley M. Prospective study on
the use of bolus intrathecal baclofen for spastic hypertonia
due to acquired brain injury. Archives of Physical Medicine
and Rehabilitation 1996; Vol. 77, issue 5:461–6.
Meythaler 1997 {published data only (unpublished sought but not
used)}
Meythaler JM, McCary A, Hadley MN. Prospective
assessment of continuous intrathecal infusion of baclofen
for spasticity caused by acquired brain injury: a preliminary
report. Journal of Neurosurgery 1997; Vol. 87, issue 3:
415–9.
Meythaler 1999a {published data only (unpublished sought but not
used)}
Meythaler JM, Guin-Renfroe S, Hadley MN. Continuously
infused intrathecal baclofen for spastic/dystonic hemiplegia:
29Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
a preliminary report. American Journal of Physical
Medicine & Rehabilitation 1999; Vol. 78, issue 3:247–54.
Meythaler 1999b {published data only (unpublished sought but not
used)}
Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN.
Long-term continuously infused intrathecal baclofen for
spastic-dystonic hypertonia in traumatic brain injury:
1-year experience. Archives of Physical Medicine and
Rehabilitation 1999; Vol. 80, issue 1:13–9.
NCT00287157 {published data only (unpublished sought but not
used)}
NCT00287157. Pilot, proof-of-concept study of sublingual
tizanidine in children with chronic traumatic brain injury
(TBI). clinicaltrials.gov/ct2/show/NCT00287157 Date first
received: 6 February 2006.
Pittaccio 2013 {published data only}
Pittaccio S, Garavaglia L, Viscuso S, Beretta E, Strazzer S.
Implementation, testing and pilot clinical evaluation of
superelastic splints that decrease joint stiffness. Annals of
Biomedical Engineering 2013;41:2003–17.
Verplancke 2005 {published data only}
Verplancke D, Snape S, Salisbury CF, Jones PW, Ward AB.
A randomized controlled trial of botulinum toxin on lower
limb spasticity following acute acquired severe brain injury.
Clinical Rehabilitation 2005; Vol. 19, issue 2:117–25.
References to studies excluded from this review
Armstrong 1997 {published data only}
Armstrong RW, Steinbok P, Cochrane DD, Kube SD,
Fife SE, Farrell K. Intrathecally administered baclofen for
treatment of children with spasticity of cerebral origin.
Journal of Neurosurgery 1997;87(3):409–14.
Ashby 1972 {published data only}
Ashby P, Burke D, Rao S, Jones RF. Assessment of
cyclobenzaprine in the treatment of spasticity. Journal of
Neurology, Neurosurgery, and Psychiatry 1972; Vol. 35,
issue 5:599–605.
Baricich 2008 {published data only}
Baricich A, Carda S, Bertoni M, Maderna L, Cisari C. A
single-blinded, randomized pilot study of botulinum toxin
type a combined with non-pharmacological treatment for
spastic foot. Journal of Rehabilitation Medicine 2008; Vol.
40, issue 10:870–2.
Barnes 2010 {published data only}
Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-
Batar A, Minnasch P. Efficacy and safety of NT 201 for
upper limb spasticity of various etiologies - a randomized
parallel-group study. Acta Neurologica Scandinavica 2010;
Vol. 122, issue 4:295–302.
Basmajian 1973 {published data only}
Basmajian JV, Super GA. Dantrolene sodium in the
treatment of spasticity. Archives of Physical Medicine and
Rehabilitation 1973; Vol. 54, issue 2:61–4.
Basmajian 1974 {published data only}
Basmajian JV, Yucel V. Effects of a GABA-derivative (BA-
34647) on spasticity. Preliminary report of a double-blind
cross-over study. American Journal of Physical Medicine
1974; Vol. 53, issue 5:223–8.
Bensmail 2010 {published data only}
Bensmail D, Robertson JVG, Fermanian C, Roby-Brami
A. Botulinum toxin to treat upper-limb spasticity in
hemiparetic patients: analysis of function and kinematics of
reaching movements. Neurorehabilitation & Neural Repair
2010; Vol. 24, issue 3:273–81.
Bes 1988 {published data only}
Bes A, Eyssette M, Pierrot-Deseilligny E, Rohmer F, Warter
JM. A multi-centre, double-blind trial of tizanidine, a new
antispastic agent, in spasticity associated with hemiplegia.
Current Medical Research and Opinion 1988; Vol. 10,
issue 10:709–18.
Bovend’Eerdt 2009 {published data only}
Bovend’Eerdt TJH, Dawes H, Sackley C, Izadi H, Wade
DT. Mental techniques during manual stretching in
spasticity - a pilot randomized controlled trial. Clinical
Rehabilitation 2009; Vol. 23, issue 2:137–45. 0269–2155]
Boyd 2001 {published data only}
Boyd RN, Dobson F, Parrott J, Love S, Oates J, Larson A, et
al. The effect of botulinum toxin type A and a variable hip
abduction orthosis on gross motor function: a randomized
controlled trial. European Journal of Neurology 2001; Vol.
8, issue Suppl 5:109–19.
Burbaud 1996 {published data only}
Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X,
Joseph PA, et al. A randomised, double blind, placebo
controlled trial of botulinum toxin in the treatment of
spastic foot in hemiparetic patients. Journal of Neurology,
Neurosurgery, and Psychiatry. 1996/09/01 1996; Vol. 61,
issue 3:265–9.
Burke 1975 {published data only}
Burke D, Hammond C, Skuse N, Jones RF. A phenothiazine
derivative in the treatment of spasticity. Journal of
Neurology, Neurosurgery, and Psychiatry 1975; Vol. 38,
issue 5:469–74.
Chang 2009 {published and unpublished data}
Chang CL, Munin MC, Skidmore ER, Niyonkuru C,
Huber LM, Weber DJ. Effect of baseline spastic hemiparesis
on recover of upper-limb function following botulinum
toxin type A injections and postinjection therapy. Archives
of Physical Medicine and Rehabilitation 2009;90:1462–7.
Childers 1996 {published data only}
Childers MK, Stacy M, Cooke DL, Stonnington HH.
Comparison of two injection techniques using botulinum
toxin in spastic hemiplegia. American Journal of Physical
Medicine & Rehabilitation 1996; Vol. 75, issue 6:462–9.
Cocchiarella 1967 {published data only}
Cocchiarella A, Downey JA, Darling RC. Evaluation of
the effect of diazepam on spasticity. Archives of Physical
Medicine and Rehabilitation 1967; Vol. 48, issue 8:393–6.
Cohan 1980 {published data only}
Cohan SL, Raines A, Panagakos J, Armitage P. Phenytoin
and chlorpromazine in the treatment of spasticity. Archives
of Neurology 1980; Vol. 37, issue 6:360–4.
30Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Copley 2013 {published data only}
Copley J, Kuipers K, Fleming J, RassafianiM. Individualised
resting hand splints for adults with acquired brain
injury: a randomized, single blinded, single case design.
Neurorehabilitation 2013;32:885–98.
Corry 1998 {published data only}
Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC,
Graham HK. Botulinum toxin A compared with stretching
casts in the treatment of spastic equinus: a randomised
prospective trial. Journal of Pediatric Orthopedics. 1998/
05/26 1998; Vol. 18, issue 3:304–11.
Fazekas 2007 {published data only}
Fazekas G, Horvath M, Troznai T, Toth A. Robot-
mediated upper limb physiotherapy for patients with spastic
hemiparesis: a preliminary study. Journal of Rehabilitation
Medicine 2007; Vol. 39, issue 7:580–2. 1650–1977]
Fietzek 2014 {published data only}
Fietzek UM, Kossmehl P, Schelosky L, Ebersbach G,
Wissel J. Early botulinum toxin treatment for spastic
pes equinovarus - a randomized double-blind placebo-
controlled study. European Journal of Neurology 2014;21:
1089–95.
Francisco 2002 {published data only}
Francisco GE, Boake C, Vaughn A. Botulinum toxin
in upper limb spasticity after acquired brain injury: a
randomized trial comparing dilution techniques. American
Journal of Physical Medicine & Rehabilitation 2002; Vol.
81, issue 5:355–63.
Gracies 2009 {published data only}
∗ Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan
S, Simpson DM. Botulinum toxin dilution and endplate
targeting in spasticity: a double-blind controlled study.
Archives of Physical Medicine and Rehabilitation 2009;
Vol. 90, issue 1:9–16.
Gracies JM, Weisz DJ, Yang BY, Flanagan S, Simpson
DM. Impact of botulinum toxin type A (BTX-A) dilution
and endplate targeting technique in upper limb spasticity
(abstract). Annals of Neurology 2002;52(Suppl 3):S87.
Grazko 1995 {published data only}
Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for
spasticity, muscle spasms, and rigidity. Neurology. 1995/
04/01 1995; Vol. 45, issue 4:712–7. 0028–3878: (Print)]
Guo 2006 {published data only}
Guo F, Yue W, Ren L, Zhang YM, Yang J. Botulinum toxin
type A plus rehabilitative training for improving the motor
function of the upper limbs and activities of daily life in
patients with stroke and brain injury. Neural Regeneration
Research 2006; Vol. 1, issue 9:859–61.
Harvey 1974 {published data only}
Harvey MS, Knight JDS, Lal R, Stockley AGI, Timney AP,
White CJ, et al. A comparative trial of dimethothiazine in
spastic conditions. A report from the General Practitioner
Research Group. Practitioner 1974; Vol. 213, issue 1273:
101–5.
Harvey 2006 {published data only}
Harvey L, de Jong I, Goehl G, Mardwedel S. Twelve
weeks of nightly stretch does not reduce thumb web-
space contractures in people with a neurological condition:
a randomised controlled trial. Australian Journal of
Physiotherapy 2006;52(4):251–8.
Hill 1994 {published data only}
Hill J. The effects of casting on upper extremity motor
disorders after brain injury. American Journal of
Occupational Therapy 1994; Vol. 48, issue 3:219–24.
Imle 1986 {published data only}
Imle PC, Eppinghaus CE, Boughton AC. Efficacy of non-
bivalved and bivalved serial casting on head injured patients
in intensive care. Physical Therapy 1986; Vol. 66:748
(abstract).
Krewer 2014 {published data only}
Krewer C, Hartl S, Müller F, Koenig E. Effects of repetitive
peripheral magnetic stimulation on upper-limb spasticity
and impairment in patients with spastic hemiparesis: a
randomized, double-blind, sham-controlled study. Archives
of Physical and Medical Rehabilitation 2014;95:1039–47.
Lannin 2003 {published data only}
Lannin NA, Horsley SA, Herbert R, McCuskey A, Cusiek
A. Splinting the hand in the functional position after brain
impairment: a randomized, controlled trial. Archives of
Physical Medicine and Rehabilitation 2003; Vol. 84, issue
2:297–302.
Leung 2012 {published data only}
Leung J, Harvey LA, Moseley AM, Tse C, Bryant J,
Wyndham S, et al. Electrical stimulation and splinting
were not clearly more effective than splinting alone for
contracture management after acquired brain injury: a
randomised trial. Journal of Physiotherapy 2012;58:231–40.
Levine 1969 {published data only}
Levine IM, Jossmann PB, Friend DG, DeAngelis V.
Prazepam in the treatment of spasticity. A quantitative
double-blind evaluation. Neurology 1969; Vol. 19, issue 5:
510–6.
Levine 1977 {published data only}
Levine IM, Jossmann PB, DeAngelis V. Liorseal, a new
muscle relaxant in the treatment of spasticity - a double-
blind quantitative evaluation. Diseases of the Nervous
System 1977; Vol. 38, issue 12:1011–5.
Mancini 2005 {published data only}
Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A
randomised, double-blind, dose-ranging study to evaluate
efficacy and safety of three doses of botulinum toxin type
A (Botox) for the treatment of spastic foot. Neurological
Sciences 2005; Vol. 26, issue 1:26–31. 1590–1874]
Martin 2014 {published data only}
Martin A, Abogunrin S, Kurth H, Dinet J. Epidemiological,
humanistic, and economic burden of illness of lower limb
spasticity in adults: a systematic review. Neuropsychiatric
Disease and Treatment 2014;10:111–22.
31Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mayer 2008 {published data only}
Mayer NH, Whyte J, Wannstedt G, Ellis CA. Comparative
impact of 2 botulinum toxin injection techniques for elbow
flexor hypertonia. Archives of Physical Medicine and
Rehabilitation 2008; Vol. 89, issue 5:982–7.
McPherson 1982 {published data only}
McPherson JJ, Kreimeyer D, Aalderks M, Gallagher T. A
comparison of dorsal and volar resting hand splints in the
reduction of hypertonus. American Journal of Occupational
Therapy 1982; Vol. 36, issue 10:664–70.
Meythaler 2001b {published data only}
Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM.
Prospective assessment of tizanidine for spasticity due to
acquired brain injury. Archives of Physical Medicine and
Rehabilitation 2001; Vol. 82, issue 9:1155–63.
Middel 1997 {published data only}
Middel B, KuipersUpmeijer H, Bouma J, Staal M, Oenema
D, Postma T, et al. Effect of intrathecal baclofen delivered
by an implanted programmable pump on health related
quality of life in patients with severe spasticity. Journal of
Neurology, Neurosurgery and Psychiatry 1997; Vol. 63,
issue 2:204–9.
Moseley 1997 {published data only}
Moseley AM. The effect of casting combined with stretching
on passive ankle dorsiflexion in adults with traumatic head
injuries. Physical Therapy 1997; Vol. 77, issue 3:240–7.
0031–9023: (Print)]
Moseley 2008 {published data only}
Moseley AM, Hassett LM, Leung J, Clare JS, Herbert
RD, Harvey LA. Serial casting versus positioning for the
treatment of elbow contractures in adults with traumatic
brain injury: a randomized controlled trial. Clinical
Rehabilitation 2008; Vol. 22, issue 5:406–17.
Nakhostin 2009 {published data only}
Nakhostin Ansari N, Naghdi S, Hasson S, Rastgoo M.
Efficacy of therapeutic ultrasound and infrared in the
management of muscle spasticity. Brain Injury 2009; Vol.
23, issue 7–8:632–8.
NCT00776048 {published data only}
NCT00776048. Validation of an obstacle course used in
patients with muscle tightness. clinicaltrials.gov/ct2/show/
study/NCT00776048 Date first received: 20 October
2008.
NCT00900666 {published data only}
NCT00900666. Efficacy of botulinum toxin Injections in
the rectus femoris to treat stiff knee gait following acquired
brain injury. clinicaltrials.gov/ct2/show/NCT00900666
Date first received: 13 May 2009.
Pagano 1990 {published data only}
Pagano MA, Frerreiro ME, Herskovits. Study using
Tizanidina and Baclofen in patients with chronic spasticity.
Revista Neurológica Argentina 1990; Vol. 15, issue 1:
27–33.
Penn 1988 {published data only}
Penn RD. Intrathecal baclofen for severe spasticity. Annals
of the New York Academy of Sciences 1988; Vol. 531:
157–66.
Richardson 2000 {published data only}
∗ Richardson D, Sheean G, Werring D, Desai M, Edwards
S, Greenwood R, et al. Evaluating the role of botulinum
toxin in the management of focal hypertonia in adults.
Journal of Neurology, Neurosurgery, and Psychiatry 2000;
Vol. 69, issue 4:499–506.
Thompson AJ, Richardson D, Sheehan G, Desai M,
Werring D, Edwards S, et al. Evaluating the role of
botulinum toxin type A in adults with focal spasticity.
European Journal of Neurology 1999;6(Suppl 4):S75.
Roussan 1985 {published data only}
Roussan M, Terrence C, Fromm G. Baclofen versus
diazepam for the treatment of spasticity and long-term
follow-up of baclofen therapy. Pharmatherapeutica 1985;
Vol. 4, issue 5:278–84.
Sahuquillo 2000 {published data only}
Sahuquillo J, Robles A, Poca A, Ballabriga A, Mercadal J,
Secades JJ. A controlled, double-blind, randomized pilot
clinical trial of nicardipine as compared with a placebo in
patients with moderate or severe head injury. Revista de
Neurologia 2000; Vol. 30, issue 5:401–8.
Simpson 1996 {published data only}
Simpson DM, Alexander DN, O’Brien CF, Tagliati M,
Aswad AS, Leon JM, et al. Botulinum toxin type A in the
treatment of upper extremity spasticity: a randomized,
double-blind, placebo-controlled trial. Neurology 1996;
Vol. 46, issue 5:1306–10.
Simpson 2009 {published data only}
Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear
A, BoNT/TZD Study Team. Botulinum neurotoxin versus
tizanidine in upper limb spasticity: a placebo-controlled
study. Journal of Neurology, Neurosurgery, and Psychiatry
2009; Vol. 80, issue 4:380–5.
Smith 2000 {published data only}
Smith SJ, Ellis E, White S, Moore AP. A double-blind
placebo-controlled study of botulinum toxin in upper limb
spasticity after stroke or head injury. Clinical Rehabilitation
2000; Vol. 14, issue 1:5–13.
Snow 1990 {published data only}
Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA,
Calne DB. Treatment of spasticity with botulinum toxin: a
double-blind study. Annals of Neurology 1990; Vol. 28,
issue 4:512–5. 0364–5134: (Print)]
Suputtitada 2005 {published data only}
Suputtitada A, Suwanwela NC. The lowest effective dose
of botulinum A toxin in adult patients with upper limb
spasticity. Disability & Rehabilitation 2005; Vol. 27, issue
4:176–84.
Thibaut 2015 {published data only}
Thibaut A, Deltombe T, Wannez S, Gosseries O, Ziegler E,
Dieni C, et al. Impact of soft splints on upper limb spasticity
in chronic patients with disorders of consciousness: a
32Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
randomized, single-blind, controlled trial. Brain Injury
2015;29:830–6.
Van Schaeybroeck 2000 {published data only}
Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E,
Borghgraef C, Feys P. Intrathecal baclofen for intractable
cerebral spasticity: a prospective placebo-controlled, double-
blind study. Neurosurgery 2000; Vol. 46, issue 3:603–9.
Yelnik 2007 {published data only}
Yelnik AP, Colle FM, Bonan IV, Vicaut E. Treatment of
shoulder pain in spastic hemiplegia by reducing spasticity
of the subscapular muscle: a randomised, double blind,
placebo controlled study of botulinum toxin A. Journal of
Neurology, Neurosurgery and Psychiatry 2007; Vol. 78,
issue 8:845–8.
Zhao 2015 {published data only}
Zhao W, Wang C, Li Z, Chen L, Li J, Cui W, et al. Efficacy
and safety of transcutaneous electrical acupoint stimulation
to treat muscle spasticity following brain injury: a double-
blinded, multicenter, randomized controlled trial. PLoS
One 2015;2:e0116976.
References to studies awaiting assessment
2009-015868-34 {published data only}
A phase III, multicentre, double-blind, prospective,
randomized, placebo-controlled study, assessing the efficacy
and safety of Dysport® used for the treatment of lower-limb
spasticity in adult subjects with hemiparesis due to stroke
or traumatic brain injury. www.clinicaltrialsregister.eu/
ctr-search/search?query=eudract˙number:2009-015868-34
Date first received: 15 February 2011.
EUCTR2011-005375-16-SE {published data only (unpublished
sought but not used)}
A phase III prospective, multi-center, randomised evaluator-
blinded study to compare neuromuscular junction
(NMJ) targeted technique for Dysport injectives in
upper limb spasticity post stroke or traumatic brain
injury to the technique used in clinical practice.
www.clinicaltrialsregister.eu/ctr-search/trial/2011-005375-
16/results Date first received: 24 September 2012.
Gracies 2016 {published data only}
Gracies JM, Esquenazi A, Brashear A, Edgley SR, O’Dell M,
Hedera P, et al. Poster 288. Efficacy and safety of repeated
abobotulinumtoxinA injections in adults with lower limb
spasticity. PM & R : the Journal of Injury, Function, and
Rehabilitation 2016;8:S254.
Ipsen. Dysport® adult lower limb spasticity follow-on
study. clinicaltrials.gov/ct2/show/NCT01251367 Date first
received: 1 December 2010.
IRCT2014041112777N {published data only}
∗ Rasras S. Comparative efficacy of cyproheptadine and
baclofen on spasticity in patients with head trauma.
en.search.irct.ir/view/17738 Date first received: 13 May
2014.
Rasras S, Fallahpour S, Zeinali M, Soltani A, Bahrami
R, Teymoori AR, et al. Survey effect of cyproheptadine-
baclofen and cyproheptadine baclofen-thizanidine regimens
on spasticity in patients with traumatic brain injury. Asian
Journal of Medical and Pharmaceutical Researches 2014;4:
142–6.
NCT02052024 {published data only}
NCT02052024. Myobloc atrophy study (MAS).
Clinicaltrials.gov/show/NCT02052024 Date first received:
31 January 2014.
References to ongoing studies
ACTRN12615000821594 {published data only}
ACTRN12615000821594. Effectiveness of combining
serial casting and botulinum toxin for the management
of ankle contractures after traumatic brain injury: a
randomised controlled study. www.anzctr.org.au/Trial/
Registration/TrialReview.aspx?id=365685 Date first
received: 10 August 2015.
Additional references
Ada 2006a
Ada L, O’Dwyer N, O’Neill E. Relation between spasticity,
weakness and contracture of the elbow flexors and upper
limb activity after stroke: an observational study. Disability
and Rehabilitation 2006; Vol. 28, issue 13–14:891–7.
Ada 2006b
Ada L, Dorsch S, Canning CG. Strengthening interventions
increase strength and improve activity after stroke: a
systematic review. Australian Journal of Physiotherapy
2006; Vol. 52, issue 4:241–8.
Ade-Hall 2000
Ade-Hall R, Moore P. Botulinum toxin type A in the
treatment of lower limb spasticity in cerebral palsy. Cochrane
Database of Systematic Reviews 2000, Issue 1. [DOI:
10.1002/14651858.CD001408
Allison 1995
Allison SC, Abraham LD. Correlation of quantitative
measures with the modified Ashworth Scale in the
assessment of plantar flexor spasticity in patients with
traumatic brain injury. Journal of Neurology 1995; Vol.
242, issue 10:699–706.
Amatya 2013
Amatya B, Khan F, La ML, Demetrios M, Wade DT. Non
pharmacological interventions for spasticity in multiple
sclerosis. Cochrane Database of Systematic Reviews 2013,
Issue 2. [DOI: 10.1002/14651858.CD009974.pub2
Ashworth 2012
Ashworth NL, Satkunam LE, Deforge D. Treatment for
spasticity in amyotrophic lateral sclerosis/motor neuron
disease. Cochrane Database of Systematic Reviews 2012, Issue
2. [DOI: 10.1002/14651858.CD004156.pub4
Aydin 2005
Aydin G, Tomruk S, Kele I, Demir S, Orkun S.
Transcutaneous electrical nerve stimulation versus baclofen
in spasticity: clinical and electrophysiologic comparison.
American Journal of Physical Medicine & Rehabilitation
2005; Vol. 84, issue 8:584–92. [0894–9115]
33Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Baker 2015
Baker JA, Pereira G. The efficacy of botulinum toxin A
on improving ease of care in the upper and lower limbs:
a systematic review and meta-analysis using the Grades
of Recommendation, Assessment, Development and
Evaluation approach. Clinical Rehabilitation 2015;29:
731–40.
Becker 1997
Becker R, Alberti O, Bauer BL. Continuous intrathecal
baclofen infusion in severe spasticity after traumatic or
hypoxic brain injury. Journal of Neurology 1997; Vol. 244,
issue 3:160–6.
Bragge 2016
Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ,
Rosenfeld JV, et al. A state of the science overview of
randomised controlled trials evaluating acute management
of moderate to severe traumatic brain injury. Journal of
Neurotrauma 2016;33(16):1461–78.. [DOI: 10.1089/
neu.2015.4233
Brashear 2002
Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez
N, Gracies JM, Gordon MF, et al. Inter- and intrarater
reliability of the Ashworth Scale and the Disability
Assessment Scale in patients with upper-limb poststroke
spasticity. Archives of Physical and Medical Rehabilitation
2002;83:1349–54.
Brashear 2016
Brashear A, Elovic E. Why is spasticity important?.
Spasticity: Diagnosis and Management. New York (NY):
Demos Medical Publishing, 2016:3–4.
Brazinova 2016
Brazinova A, Rehorcikova V, Taylor MS, Buckova V,
Majdan M, Psota M, et al. Epidemiology of Traumatic
Brain Injury in Europe: A Living Systematic Review.
Journal of Neurotrauma 2016:Epub ahead of print. [DOI:
10.1089/neu.2015.4126
Dashtipour 2016
Dashtipour K, Chen JJ, Walker HW, Lee MY. Systematic
literature review of abobotulinumtoxinA in clinical trials for
lower limb spasticity. Medicine 2016;95:e2468.
Demetrios 2013
Demetrios M, Khan F, Turner-Stokes L, Brand C,
McSweeney S. Multidisciplinary rehabilitation following
botulinum toxin and other focal intramuscular treatment
for post-stroke spasticity. Cochrane Database of
Systematic Reviews 2013, Issue 6. [DOI: 10.1002/
14651858.CD009689.pub2
Dong 2017
Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of
botulinum toxin type A for upper limb spasticity after
stroke or traumatic brain injury: a systematic review with
meta-analysis and trial sequential analysis. European Journal
of Physical Rehabilitation Medicine 2017;53:256–67.
Duarte 2016
Duarte GS, Castelão M, Rodrigues FB, Marques RE,
Ferreira J, Sampaio C, et al. Botulinum toxin type A versus
botulinum toxin type B for cervical dystonia. Cochrane
Database of Systematic Reviews 2016, Issue 10. [DOI:
10.1002/14651858.CD004314.pub3
Esquenazi 2006
Esquenazi A. Improvements in healthcare and cost benefits
associated with botulinum toxin treatment of spasticity and
muscle overactivity. European Journal of Neurology 2006;
Vol. 13 (Suppl 4):27–34.
Fleuren 2010
Fleuren JFM, Voerman GE, Erren-Wolters CV, Snoek GJ,
Rietman JS, Hermens HJ, et al. Stop using the Ashworth
Scale for the assessment of spasticity. Journal of Neurology,
Neurosurgery and Psychiatry 2010; Vol. 81, issue 1:46–52.
Francis 2004
Francis HP, Wade DT, Turner-Stokes L, Kingswell RS,
Dott CS, Coxon EA. Does reducing spasticity translate into
functional benefit? An exploratory meta-analysis. Journal
of Neurology, Neurosurgery and Psychiatry 2004; Vol. 75,
issue 11:1547–51.
Giovannelli 2007
Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli
C. Early physiotherapy after injection of botulinum toxin
increases the beneficial effects on spasticity in patients with
multiple sclerosis. Clinical Rehabilitation. London: SAGE
PUBLICATIONS, INC., 2007; Vol. 21, issue 4:331–7.
[02692155]
Guyatt 2011
Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello
P, Rind D, et al. GRADE guidelines 6. Rating the quality
of evidence - imprecision. Journal of Clinical Epidemiology
2011;64:1283–93.
Hall 1993
Hall KM, Hamilton BB, Gordon WA, Zasler ND.
Characteristics and comparisons of functional assessment
indices: disability rating scale, functional independence
measure, and functional assessment measure. Journal of
Head Trauma Rehabilitation 1993;8:60–74.
Haugh 2006
Haugh AB, Pandyan AD, Johnson GR. A systematic review
of the Tardieu Scale for the measurement of spasticity.
Disability and Rehabilitation 2006; Vol. 28, issue 15:
899–907.
Higgins 2011
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher
D, Oxman AD, et al. Cochrane Bias Methods Group,
Cochrane Statistical Methods Group. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised
trials. BMJ 2011;343:d5928.
Hoare 2010
Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki
HB, Carey L. Botulinum toxin A as an adjunct to
treatment in the management of the upper limb in children
with spastic cerebral palsy (update). Cochrane Database
of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/
14651858.CD003469.pub4
34Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hsieh 2012
Hsieh JTC, Wolfe DL, McIntyre A, Janzen S, Townson AF,
Short C, et al. Spasticity following spinal cord injury. In:
Eng JJ, Teasell RW, Miller WC, Wolfe DL, Townson AF,
Hsieh JTC, et al. editor(s). Spinal Cord Injury Rehabilitation
Evidence, Version 4.0. Vancouver (BC): SCIRE Project,
2012.
Jennett 1975
Jennett B, Bond M. Assessment of outcome after severe
brain damage. Lancet 1975;1:480–4.
Keith 1987
Keith RA, Granger CV, Hamilton BB, Sherwin FS.
The functional independence measure: a new tool for
rehabilitation. Advances in Clinical Rehabilitation 1987;1:
6–18.
Khan 2003
Khan F, Baguley IJ, Cameron ID. Rehabilitation after
traumatic brain injury. Medical Journal of Australia. 2003/
03/14 2003; Vol. 178, issue 6:290–5.
Kiresuk 1994
Kiresuk TJ, Smith A, Cardillo JE. Goal Attainment Scaling:
Applications, Theory, and Measurement. Hillsdale (NJ):
Lawrence Erlbaum Associates, 1994.
Kwakkel 1999
Kwakkel G, Wagenaar R, Twisk J, Lankhorst G, Koetsier
J. Intensity of leg and arm training after primary middle-
cerebral-artery stroke: a randomised trial. Lancet 1999;
Vol. 354:191–6.
Lance 1980
Lance J. Pathophysiology of spasticity and clinical
experience with baclofen. In: Lance JWFR, Young RR,
Koella WP editor(s). Spasticity: Disordered Motor Control.
Chicago (IL): Year Book Medical Publishers, 1980.
Law 2000
Law M, Baptiste S, Carswell A, McColl MA, Polatajko H,
Pollock N. Canadian Occupational Performance Measure.
Canada: CAOT Publications, 2000.
Lindsay 2013
Lindsay C, Pandyan AD. Pharmacological interventions
other than botulinum toxin for spasticity after stroke.
Cochrane Database of Systematic Reviews 2013, Issue 2.
[DOI: 10.1002/14651858.CD010362.pub2
Maas 2008
Maas AI, Stocchetti N, Bullock R. Moderate and severe
traumatic brain injury in adults. Lancet Neurology. 2008/
07/19 2008; Vol. 7, issue 8:728–41.
Maas 2010
Maas AIR, Steyerberg EW, Marmarou A, McHugh GS,
Lingsma HF, Butcher I, et al. IMPACT recommendations
for improving the design and analysis of clinical trials in
moderate to severe traumatic brain injury. Neurotherapeutics
2010;7:127–34.
Malhotra 2009
Malhotra S, Pandyan AD, Day CR, Jones PW, Hermens H.
Spasticity, an impairment that is poorly defined and poorly
measured. Clinical Rehabilitation 2009;23:651–8.
Manchester 1997
Manchester D, Hodgkinson A, Casey T. Prolonged, severe
behavioural disturbance following traumatic brain injury:
what can be done?. Brain Injury 1997;11:605–17.
McGuire 2016
McGuire J. Epidemiology of spasticity in the adult and
child. In: Brashear A editor(s). Spasticity: Diagnosis
and Management. 2nd Edition. New York (NY): Demos
Medical Publishing, 2016.
Mehrholz 2005
Mehrholz J, Major Y, Meissner D, Sandi-Gahun S, Koch
R, Pohl M. The influence of contractures and variation
in measurement stretching velocity on the reliability of
the Modified Ashworth Scale in patients with severe brain
injury. Clinical Rehabilitation 2005; Vol. 19, issue 1:
63–72.
Meythaler 2001a
Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM.
Prospective assessment of tizanidine for spasticity due to
acquired brain injury. Archives of Physical Medicine and
Rehabilitation 2001; Vol. 82, issue 9:1155–63.
Morris 2002
Morris S. Ashworth and Tardieu Scales: their Clinical
Relevance for Measuring Spasticity in Adult and Paediatric
Neurological Populations. Physical Therapy Reviews 2002;
Vol. 7, issue 1:53–62.
Mortenson 2003
Mortenson PA, Eng JJ. The use of casts in the management
of joint mobility and hypertonia following brain injury
in adults: a systematic review. Physical Therapy 2003;83:
648–58.
Nair 2014
Nair KPS, Marsden J. The management of spasticity in
adults. BMJ 2014;349:g4737.
O’Dell 2015
O’Dell MW, Walker HW, Edgley SR, Gracies JM, Gul F,
Wimmer M, et al. AbobotulinumtoxinA (Dysport®) in the
treatment of adult patients with upper limb spasticity due
to traumatic brain injury. PM & R : the Journal of Injury,
Function, and Rehabilitation 2015;7:S103.
Olver 2010
Olver J, Esquenazi A, Fung VSC, Singer BJ, Ward AB.
Botulinum toxin assessment, intervention and aftercare
for lower limb disorders of movement and muscle tone in
adults: international consensus statement. European Journal
of Neurology 2010;17:57–73.
Pandyan 1999
Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes
MP, Rodgers H. A review of the properties and limitations
of the Ashworth and modified Ashworth Scales as measures
of spasticity. Clinical Rehabilitation 1999; Vol. 13, issue 5:
373–83.
Pandyan 2005
Pandyan A, Gregoric M, Barnes M, Wood D, Van Wijck
F, Burridge J, et al. Spasticity: clinical perceptions,
35Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
neurological realities and meaningful measurement.
Disability and Rehabilitation 2005; Vol. 27:2–6.
Parke 1989
Parke B, Penn RD, Savoy SM, Corcos D. Functional
outcome after delivery of intrathecal baclofen. Archives of
Physical Medicine and Rehabilitation 1989; Vol. 70, issue
1:30–2.
Patrick 2006
Patrick E, Ada L. The Tardieu Scale differentiates
contracture from spasticity whereas the Ashworth Scale is
confounded by it. Clinical Rehabilitation 2006;20:173–82.
Pierson 1996
Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the
treatment of spasticity: functional implications and patient
selection. Archives of Physical Medicine and Rehabilitation
1996; Vol. 77, issue 7:717–21.
RCP 2009
Royal College of Physicians. Spasticity in Adults:
Management using Botulinum Toxin: National Guidelines.
London (UK): Royal College of Physicians, 2009.
RevMan 2011 [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2011.
Ryan 2016
Ryan R, Hill S. How to GRADE the quality of the
evidence. Cochrane Consumers and Communication
Group, Version 3.0 December 2016. cccrg.cochrane.org/
sites/cccrg.cochrane.org/files/public/uploads/
how˙to˙grade˙revising˙1˙december˙2016.pdf (accessed
prior to 25 October 2017).
Schünemann 2011
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ’Summary of findings’ tables. In: Higgins JP, Green
S, editor(s). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Shakespeare 2003
Shakespeare D, Boggild M, Young CA. Anti-spasticity
agents for multiple sclerosis. Cochrane Database of
Systematic Reviews 2003, Issue 4. [DOI: 10.1002/
14651858.CD001332; CD001332
Singer 2004
Singer BJ, Jegasothy GM, Singer KP, Allison GT, Dunne
JW. Incidence of ankle contracture after moderate to severe
acquired brain injury. Archives of Physical Medicine and
Rehabilitation. 2004/09/18 2004; Vol. 85, issue 9:1465–9.
Summers 2009
Summers CR, Ivins B, Schwab KA. Traumatic brain injury
in the United States: an epidemiologic overview. Mount
Sinai Journal of Medicine 2009; Vol. 76, issue 2:105–10.
Taricco 2000
Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological
interventions for spasticity following spinal cord injury.
Cochrane Database of Systematic Reviews 2000, Issue 2.
[DOI: 10.1002/14651858.CD001131
Teasdale 1974
Teasdale G, Jennett B. Assessment of coma and impaired
consciousness. Lancet 1974;304:814.
Wedekind 2005
Wedekind C, Lippert-Grüner M. Long-term outcome in
severe traumatic brain injury is significantly influenced by
brainstem involvement. Brain Injuries 2005;19:681–4.
WHO 2010
World Health Organization. International Classification
of Functioning, Disability & Health. apps.who.int/
classifications/icfbrowser/ (accessed 2 July 2010).
Williams 2015a
Williams G, Banky M, Olver J. Severity and distribution of
spasticity does not limit mobility or influence compensatory
strategies following traumatic brain injury. Brain Injury
2015;29(10):1232–8.
Williams 2015b
Williams G, Banky M, Olver J. Distribution of lower limb
spasticity does not influence mobility outcome following
traumatic brain injury: an observational study. Journal of
Head Trauma Rehabilitation 2015;30(5):E49–57.
Wood 1999
Wood RL, McCrea JD, Wood LM, Merriman RN. Clinical
and cost effectiveness of post-acute neurobehavioural
rehabilitation. Brain Injury 1999;13:69–88.
Wood 2008
Wood L, Egger M, Gluud LL, Schulz K, Jüni P, Altman
DG, et al. Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions
and outcomes: meta-epidemiological study. BMJ 2008;
336:601–5.
Yelnik 2009
Yelnik AP, Simon O, Bensmail D, Chaleat-Valayer E, Decq
P, Dehail P, et al. Drug treatments for spasticity. Annals of
Physical & Rehabilitation Medicine 2009; Vol. 52, issue
10:746–56.
∗ Indicates the major publication for the study
36Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gracies 2015
Methods Randomised controlled trial (3 arms).
Setting: 34 neurology or rehabilitation clinics in 9 countries (Belgium, Czech Republic,
France, Hungary, Italy, Poland, Russia, Slovakia, USA)
Funding: Ipsen (pharmaceutical company).
Participants Total participants: 243 overall study, including 23 with TBI (65% male), for whom
results were presented separately. Number of participants in each study arm: 9 (placebo)
, 8 (abobotulinumtoxinA 500 U) and 6 (abobotulinumtoxinA 1000 U)
Adults: 23, children: 0.
People with TBI: mean age 35 years (SD 13, range not reported)
Inclusion criteria:
• aged 18-80 years;
• hemiparesis for at least 6 months post TBI (or stroke);
• Modified Ashworth Scale score in the target muscle group ≥ 2 (if never had
botulinum toxin injection) or ≥ 3 (if had botulinum toxin A injection before);
• Disability Assessment Scale score ≥ 2 on the principal target of treatment;
• spasticity angle of least 10° in the primary target muscle group and
• mean Modified Frenchay Score of 1-8 (out of possible 10).
Exclusion criteria:
• major limitations of passive range of motion in the paretic limb;
• intrathecal baclofen or physiotherapy initiated < 4 weeks prior to expected
enrolment;
• anticipated botulinum toxin A treatment during study period;
• administration of any alcohol or phenol in the study limb any time before the
study;
• previous primary or secondary non-response to any botulinum toxin for the
targeted condition;
• previous surgery to treat spasticity of the affected upper limb;
• any medical disorder increasing the risk of adverse events from botulinum toxin A
administration;
• major additional neurological impairment that could affect functional
performance;
• known disease of the neuromuscular junction;
• known sensitivity to botulinum toxin or any excipient of Dysport;
• infection at the injection site(s);
• any current or planned treatment that interferes with neuromuscular function;
• pregnant or women not willing to use contraception.
Location of spasticity:
• upper limb: elbow flexors, wrist flexors, finger flexors.
For each participant, the investigators selected themost hypertonicmuscle group (defined
by Modified Ashworth Scale score) out of elbow flexors, wrist flexors and finger flexors,
and gave an additional injection to 2 other muscle groups (including these groups +
shoulder extensors)
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Gracies 2015 (Continued)
Interventions AbobotulinumtoxinA 500 U: 2 vials (1 of placebo and 1 of abobotulinumtoxinA 500
U) were each diluted with 2.5 mL saline and combined into a single injection of 5 mL
solution. This was injected into target muscle group and at least 2 other muscle groups
(guided by electrical stimulation to identify the correct location)
AbobotulinumtoxinA 1000 U: same as above (except 2 vials of active compound were
used)
Placebo: same as above (except 2 vials of placebo were used).
Outcomes Outcome assessed at: baseline, and 1, 4 and 12 weeks.
Primary outcomes:
• spasticity/muscle tone: Tardieu Scale (at 4 weeks);
• safety assessments (adverse events).
Secondary outcomes:
• upper limb function using the Disability Assessment Scale (4-point scale);
• quality of life (subscores of the SF-36 and the EQ-5D).
Length of follow-up: 12 weeks.
Notes The full study (Gracies 2015) included more than just participants with TBI, but the
results for participants with TBI were presented separately in the conference abstract
by (O’Dell 2015). However, these results did not distinguish between different dosages
and reported results as if for a 2-armed trial (abobotulinumtoxinA 550 U and abobo-
tulinumtoxinA 1000 U vs placebo). This study also measured spasticity using the Mod-
ified Ashworth Scale, but we reported Tardieu Scale results given we prespecified this as
our preferred measure. The authors also used the Physician Global Assessment scale for
assessing the ’severity’ of a condition. Given this is not a brain injury or rehabilitation-
specific measure, neither is it clear which functional domain this outcome fitted within,
this outcome was not included in the review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were randomly allocated in a ra-
tio of 1:1:1.... Computer-generated ran-
domisation lists were created by a sponsor
statistician independent from the study...
” Furthermore, “randomisation was strati-
fied by botulinum-toxin-A treatment status
at baseline only... irrespective of the cen-
tre of recruitment or of the cause of spastic
paresis.... no rationale exists for stratifica-
tion of patients by cause [stroke and trau-
matic brain injury].”
Allocation concealment (selection bias) Low risk “Computer-generated randomisation lists
were created by a sponsor statistician in-
dependent from the study and treatment
numbers were assigned when patients en-
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Gracies 2015 (Continued)
tered the study with a 24-h interactive re-
sponse system from an external contract re-
search organisation...”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A double-dummy technique was used to
maintain masking of patients and inves-
tigators. A treatment pack contained two
vials of abobotulinumtoxinA 500 U (1000
U group), one vial of abobotulinumtox-
inA 500 U plus one vial of placebo (500
U group), or two vials of placebo (placebo
group). The [treatment] packs were iden-
tical in appearance and the procedure for
reconstitution in each group was identical.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The [treatment] packs were identical in
appearance and the procedure for reconsti-
tution in each group was identical.”
Incomplete outcome data (attrition bias) Low risk In the main study (of which the TBI par-
ticipants formed a subgroup of < 10%, i.
e. 23 of 243 participants) reported that >
94% of those randomised completed the
study to 12-week follow-up and that those
lost were relatively evenly spread between
groups. Reasons for discontinuation were
provided, and ITT methods for missing
data appeared appropriate. In the subgroup
reported in a conference abstract, it would
appear that all participants with TBI were
retained within the study
Selective reporting (reporting bias) Unclear risk Study protocol was registered on clini-
caltrials.gov (NCT01313299). Outcome
data reported appeared in line with those
prospectively stated; however, for the TBI
subset of participants included in this re-
view, outcome data for different doses of
the active intervention were conflated and
results were given in the form of percent-
ages only
Baseline Imbalances Unclear risk Baseline characteristics were described as
“similar” between the 3 groups, but no spe-
cific reference was made to the those in the
TBI subgroup, wherein the differences in
years since traumatic event were larger than
for those with stroke. It is reported that
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Gracies 2015 (Continued)
“a majority” (74%) of the TBI group had
previously received botulinum toxin treat-
ment, but it was not reported whether this
differed between intervention groups and
placebo
Appropriate study design (cross-over trial
only)
Low risk Not relevant, not a cross-over trial.
Adequate washout period (cross-over trial
only)
Low risk Not relevant, not a cross-over trial.
Other bias Unclear risk Authors reported that both the “funder and
the corresponding author were jointly in-
volved in the study design, data gathering,
data management, and statistical analysis.
With the exceptionof the four authors (FC,
BBDF, CV, and PP) who were employees
of the funder, the funder had no role in the
interpretation of the data or in the decision
to submit the manuscript for publication.
The funder funded editorial assistance pro-
vided during the writing of themanuscript.
All authors had full access to all the data
in the study and final responsibility for the
decision to submit the paper for publica-
tion.”
Leung 2014
Methods Randomised controlled trial.
Setting: Sydney, Australia (Royal Rehabilitation Centre, Liverpool and Westmead Hos-
pitals)
Funding: Royal Rehabilitation Centre, Sydney and University of Sydney
Participants Total participants: 36.
Number of participants in each study arm: intervention group 18, control group 18
Adults 36, children 0.
People with TBI: 36, mean age: intervention 38 years (SD 14); control 38 years (SD 15)
Inclusion criteria:
• first TBI;
• FIM Walking domain ≤ 4;
• ankle contracture;
• ability to participate in assessment and intervention;
• no unstable medical conditions or ankle fracture;
• no other neurological condition;
• hospital stay > 6 weeks;
• no botox injection to ankle joint in past 3 months.
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Leung 2014 (Continued)
Exclusion criteria: not reported.
Location of spasticity: gastrocnemius.
Interventions Intervention: 30 minutes of tilt table standing with electrical stimulation to the ankle
dorsiflexors 5 times a week, with 12 hours of ankle splinting a day, at least 5 days a week
(total duration of intervention programme: 6 weeks)
Control: tilt table standing for 30 minutes, 3 times a week (total duration of control
programme: 6 weeks)
Outcomes Outcome assessed at: baseline, and weeks 6 and 10 (follow-up)
Primary outcomes:
• passive ankle dorsiflexion measured at 12 Nm.
Secondary outcomes:
• passive dorsiflexion measured 3, 5, 7, 9 Nm;
• FIM Walking domain;
• walking speed;
• spasticity (ankle plantarflexor muscle spasticity was rated based on reaction to
passive stretch at high speed (not angle of catch) using the 5-point Tardieu Scale);
• physiotherapist and participant global perceived effect of treatment and treatment
credibility.
Length of follow-up: 10 weeks.
Notes Contacted author (J Leung) in April 2017 to confirmwhether participants had spasticity,
given spasticity was measured at baseline and as an outcome measure, but this was not
mentioned as an inclusion criteria. The author confirmed that 35/36 participants had
spasticity during the study, which we decided was sufficient to meet the inclusion criteria
for this review
We selected the study’s primary outcome of passive dorsiflexion (measured at 12 Nm of
torque) as the measure to include under our review outcome, Neuromusculoskeletal and
movement-related functions. The other dorsiflexion measures were not included in the
review to avoid selective outcome reporting
Similarly, we selected walking speed over the FIM Walking domain as the most appro-
priate measure of mobility in the review. The FIM Walking domain was not included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “All participants were randomly allocated
to one of two groups using a blocked ran-
domisation schedule” and “The random
allocation sequence was computer-gener-
ated.”
Allocation concealment (selection bias) Low risk “The random allocation sequence was
computer-generated by a person not in-
volved in participant recruitment. Group
allocation was concealed using consecu-
tively numbered, sealed, opaque envelopes,
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which were kept off-site.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Assessors andmedical staff were blinded to
group allocation, but treating physiothera-
pists and participants were not.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The outcomes were measured by one of
the five blinded and trained assessors who
assessed participants of both groups” and
“The blinding of the assessors was reason-
ably successful. Assessors were unblinded
in two of the end-of-intervention assess-
ments and one of the follow-up assess-
ments. In two of these assessments, a third
person, who was otherwise not involved in
the study, was asked to take the readings
from the dynamometer for the passive an-
kle range.” While the blinding was bro-
ken in some assessments, all the outcomes
included in this review were observer-re-
ported/objective
Incomplete outcome data (attrition bias) Unclear risk Participants lost to follow-up by week 10
(end of trial): 1/18 (6%) in interven-
tion group, and 3/18 (17%) in control
group. Reasons provided, and were unre-
lated to the trial. Authors reported con-
ducting an ITT analysis, without imputing
data. Given imbalance in loss to follow-up,
and relatively large percentage in 1 group,
rated as unclear
Selective reporting (reporting bias) Low risk Protocol available, all planned outcomes re-
ported.
Baseline Imbalances Unclear risk 1/36 participants did not have spasticity
during the study (unclear whether they be-
longed to intervention or control group)
and the median time from injury to base-
line assessment was longer in the interven-
tion group (140 days) compared to control
group (83 days)
Appropriate study design (cross-over trial
only)
Low risk Not relevant, not a cross-over trial.
Adequate washout period (cross-over trial
only)
Low risk Not relevant, not a cross-over trial.
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Other bias Unclear risk The number of tilt table sessions was
markedly different in the intervention
group (30 sessions) compared to the con-
trol group (18 sessions)
Meythaler 1996
Methods Randomised cross-over trial comparing bolus intrathecal baclofen and placebo
Setting: university tertiary care outpatient rehabilitation clinic.
Funding: grant R49/CCR403641 from the US Department of Health and Human Ser-
vices, Centers for Disease Control and Prevention - National Center for Injury Preven-
tion and Control to the University of Alabama-Birmingham Injury Control Research
Center
Participants Total participants 11 including 10 participants with TBI (90% male)
Adults: 11, children: 0.
People with TBI: mean age 24.0 years (SD 4.5, range 20-34).
Inclusion criteria:
• aged 18-65 years;
• diagnosis of severe chronic spastic hypertonia in the lower extremities (although
the upper extremities could also be involved) of at least 1 year’ duration that was defined
by a mean Ashworth Scale of ≥ 3 or a mean spasm score of ≥ 2, failure to respond
satisfactorily to treatment with oral antispastic medications (including baclofen at 80-
160 mg/day, and possibly diazepam, clonidine, dantrolene sodium, or a combination)
or occurrence of unacceptable adverse effects at effective treatment dosages.
Exclusion criteria:
• pregnant or failure to use an adequate contraception (if not menopausal);
• history of hypersensitivity to baclofen;
• severely impaired renal function;
• severe hepatic disease;
• severe gastrointestinal disease.
Location of spasticity:
Upper limb: shoulder abduction, elbow extensions, elbow flexion and wrist extensions
Lower limb: hip abduction, hip flexion, knee flexion and ankle dorsiflexion
The authors did not report if the participants had bilateral or unilateral symptoms
Interventions Baclofen: intrathecal administration (Lioresal Intrathecal) supplied in single-use am-
poules (10 mg/20 mL ampoules; 500 µg/mL) and diluted with preservative-free 0.9%
normal saline to obtain a concentration of 50µg/1mL. All participants received baclofen
50 µg. A lumbar puncture was performed at either the L3-L4 or the L2-L3 interspace,
and 1 mL was injected
Placebo: preservative-free normal saline.
Cross-over phase in administering the opposite treatment occurred at least 48 hours after
the initial administration
Outcomes Outcome assessed at: baseline, and 1, 2, 4 and 6 hours.
Primary outcomes:
• spasticity: Ashworth Scale, Spasm score;
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• adverse effect: complications or adverse effects were noted.
Secondary outcomes:
• deep tendon reflexes.
Length of follow-up: not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomised to receive...
” Insufficient information to determine
whether adequate random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Insufficient information to determine
whether adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the patient nor the investigator
know which substance was injected.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Before cross-over: “Neither the patient nor
the investigator know which substance was
injected. Data for the Ashworth scale,
spasm score, deep tendon reflexes were then
collected as described previously 1,2,4 and
6 hours post injection by the same investi-
gator.” After cross-over, “Again neither the
patient nor the investigator knew which
substance had been injected.”
Incomplete outcome data (attrition bias) Low risk All outcome data presented for all partici-
pants.
Selective reporting (reporting bias) Unclear risk Reported all expected outcomes but no
protocol referenced.
Baseline Imbalances Low risk Baseline data provided.
Appropriate study design (cross-over trial
only)
Low risk A cross-over study design was reasonable
due to a small sample size
Adequate washout period (cross-over trial
only)
Low risk “The crossover phase of the study occurred
during a second outpatient clinic visit at
least 48 hours after the initial administra-
tion.” Appropriate washout period for ba-
clofen
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Other bias Low risk No other bias noted.
Meythaler 1997
Methods Randomised double-blind placebo controlled cross-over trial, initial stage of trial prior
to baclofen pump insertion
Setting: outpatient rehabilitation clinic that was part of a single tertiary care university
medical centre (10 participants) and inpatients from the same university medical centre
(2 participants)
Funding: Medtronic, Inc.
Participants Total participants 12 including 9 participants with TBI (92% male)
Adults: 12, children: 0, age range 17-39 years, mean 28 years
Inclusion criteria:
• aged 10-75 years;
• diagnosis of severe chronic spastic hypertonia in lower extremities (although
upper extremities could also be involved) of ≥ 6 months’ duration that was defined by
a mean Ashworth Scale score of ≥ 3 in the affected extremities (≥ 2 extremities) or a
mean spasm score of ≥ 2 in the affected extremities;
• did not respond satisfactorily to treatment with oral antispasmodic medications
(including baclofen and possibly diazepam, clonidine, dantrolene sodium, or a
combination of these);
• experienced unacceptable adverse effects at effective treatment dosages of these
drugs.
Exclusion criteria: none reported.
Location of spasticity:
Lower extremities, upper extremities could be included, > 2 extremities affected
Interventions Baclofen: continuous intrathecal infusion of baclofen 50 µg. A lumbar puncture was
performed at either the L3-L4 or the L2-L3 interspace, and 1 mL bolus was injected.
Participants also received intensive inpatient rehabilitation to benefit from the decreased
motor tone or increased voluntary motor control (or both) they experience with the
intrathecal baclofen
Placebo: preservative-free normal saline.
Cross-over occurred during a second outpatient clinic at least 48 hours after the initial
administration
Outcomes Outcomes assessed at 1, 2, 4 and 6 hours post injection.
Primary outcome:
• Ashworth Scale, spasm frequency, deep tendon reflexes;
• adverse effects: not reported; stated “no untoward effects.”
Secondary outcomes: not reported.
Length of follow-up: not reported.
Notes No data for randomised component, prior to pump insertion. Author contacted and was
attempting to locate the data; however, no further information received
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the patient nor the investigator
knew which substance was injected until
after the second trial phase was completed.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk While the authors reported that the ’inves-
tigator’ was blinded, it was unclear if this
investigator assessed outcomes
Incomplete outcome data (attrition bias) Low risk No loss to follow-up (follow-up data for all
12 participants reported)
Selective reporting (reporting bias) Unclear risk Protocol not reported.
Baseline Imbalances Low risk Baseline imbalances unclear but not rele-
vant for a cross-over trial
Appropriate study design (cross-over trial
only)
Low risk A cross-over study design was reasonable
due to a small sample size
Adequate washout period (cross-over trial
only)
Low risk “The crossover phase of the study occurred
during a second outpatient clinic visit at
least 48 hours after the initial administra-
tion.” Appropriate washout period for ba-
clofen
Other bias High risk Unit of analysis issue. The outcomes were
analysed by looking at upper vs lower
extremities. “Rather than consider each
muscle separately, scores for muscle tone,
spasms, and reflexes were averaged for the
upper or lower extremities in each patient.
”
46Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Meythaler 1999a
Methods Single-centre, randomised, double-blind, placebo-controlled cross-over trial
Setting: spasticity clinic in a tertiary care university-based outpatient physical medicine
and rehabilitation clinic
Funding: Medtronic Inc.
Participants Total participants 6 including 3 participants with TBI (60% male)
Adults 6, children 0.
Inclusion criteria:
• aged 14-75 years;
• diagnosis of severe chronic spastic hypertonia in lower limbs (although upper
limbs could also be involved) for at least a 6-month duration that was defined by a
mean Ashworth score ≥ 3 in the affected limbs (≥ 1 limbs) or a mean spasm score ≥ 2
in the affected limb;
• either failure to respond satisfactorily to treatment with oral antispasticity
medications (including baclofen and possibly diazepam, clonidine, dantrolene sodium,
or a combination of these) or the occurrence of unacceptable adverse effects at effective
treatment dosages.
Exclusion criteria: not reported.
Location of spasticity: lower extremities, upper extremities could be included, > 2 ex-
tremities affected
Interventions Baclofen: continuous intrathecal infusion of baclofen 50 µg. A lumbar puncture was
performed at either the L3-L4 or the L2-L3 interspace, and 1 mL was injected. Partici-
pants also received intensive inpatient rehabilitation to benefit from the decreased motor
tone or increased voluntary motor control (or both) they experience with the intrathecal
baclofen
Placebo: preservative-free normal saline.
Cross-over occurred during a second outpatient clinic at least 48 hours after the initial
administration
Outcomes Outcomes assessed at 1, 2, 4 and 6 hours’ post injection.
Primary outcome:
• Ashworth Scale, spasm frequency, deep tendon reflexes;
• adverse effects: not identified; stated ”no untoward effects.
Secondary outcomes: not reported.
Length of follow-up: not reported.
Notes No data for randomised component, prior to pump insertion. Author contacted and was
attempting to locate the data; however, no further information received
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the patient nor the investigator
knew which substance was injected until
after the second trial phase was completed.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk While the authors reported that the ’inves-
tigator’ was blinded, it was unclear if this
investigator assessed outcomes
Incomplete outcome data (attrition bias) Low risk No loss to follow-up (follow-up data for all
6 participants reported)
Selective reporting (reporting bias) High risk Protocol not published but authors re-
ported they collected data at 2 time points
but only 1 time point published
Baseline Imbalances Low risk Baseline imbalances unclear but not rele-
vant for a cross-over trial
Appropriate study design (cross-over trial
only)
Low risk A cross-over study design was reasonable
due to a small sample size
Adequate washout period (cross-over trial
only)
Low risk “The crossover phase of the study occurred
during a second outpatient clinic visit at
least 48 hours after the initial administra-
tion.” Appropriate washout period for ba-
clofen
Other bias High risk Unit of analysis issue. The outcomes were
analysed by looking at upper vs lower
extremities. “Rather than consider each
muscle separately, scores for muscle tone,
spasms, and reflexes were averaged for the
upper or lower extremities in each patient.
”
Meythaler 1999b
Methods Randomised, double-blind, placebo-controlled cross-over trial
Setting: outpatient rehabilitation clinic, tertiary care university medical centre
Funding: Medtronic, Inc.
Participants Total participants: 17, all 17 participants with TBI (82% male)
Adults: not reported, children: not reported; age range: 10-55 years
Inclusion criteria:
• aged 14-75 years;
• diagnosis of severe chronic spastic hypertonia in the lower limbs (although the
upper limbs could also be involved) for ≥ 6 months that was defined by a mean
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Ashworth score ≥ 3 in the affected limbs (≥ 1 limbs) or a mean spasm score ≥ 2 in the
affected limb;
• either failure to respond satisfactorily to treatment with oral antispasticity
medications (including baclofen and possibly diazepam, clonidine, dantrolene sodium,
or a combination of these) or the occurrence of unacceptable adverse effects at effective
treatment dosages.
Exclusion criteria: not reported.
Location of spasticity: lower extremities, upper extremities could be included, > 2 ex-
tremities affected
Interventions Baclofen: continuous intrathecal infusion of baclofen 50 µg. A lumbar puncture was
performed at either the L3-L4 or the L2-L3 interspace, and 1 mL was injected. Partici-
pants also received intensive inpatient rehabilitation to benefit from the decreased motor
tone or increased voluntary motor control (or both) they experience with the intrathecal
baclofen. After implantation of the infusion device, all participants received intrathecal
baclofen 100 µg/day continuously
Placebo: preservative-free normal saline.
Cross-over occurred during a second outpatient clinic at least 48 hours after the initial
administration
Outcomes Outcomes assessed at 1, 2, 4 and 6 hours post injection, 1, 3, 6, 9 months post pump
placement
Primary outcome:
• Ashworth Scale, spasm frequency, deep tendon reflexes;
• adverse effects: not identified; stated “no untoward effects.”
Secondary outcomes: not reported.
Length of follow-up: 1 year.
Notes No data for randomised component, prior to pump insertion. Author contacted and was
attempting to locate the data; however, no further information received
“Postoperatively all patients in this study received 24 to 36 hours of intravenous van-
comycin and gentamicin for prophylaxis of infection.”
Inclusion criteria stated minimum age of 14 years, yet at least some participants as young
as 10 years
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study reported as randomised but method
not described.
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither the patient nor the investigator
knew which substance was injected until
after the second trial phase was completed.
”
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk While the authors report that the ’investi-
gator’ was blinded, it was unclear if this in-
vestigator assessed outcomes
Incomplete outcome data (attrition bias) Low risk Outcome data for all participants reported.
Selective reporting (reporting bias) Unclear risk No published protocol.
Baseline Imbalances Low risk Baseline imbalances not clear but not rele-
vant for a cross-over trial
Appropriate study design (cross-over trial
only)
Low risk A cross-over study design was reasonable
due to a small sample size
Adequate washout period (cross-over trial
only)
Unclear risk Washout period not stated.
Other bias High risk Unit of analysis issue. Outcomes were anal-
ysed by looking at upper vs lower extrem-
ities. “Rather than consider each muscle
separately, scores for muscle tone, spasms,
and reflexes were averaged for the upper or
lower extremities in each patient.”
NCT00287157
Methods Randomised, double-blind, cross-over trial (no information provided about randomisa-
tion method): Phase 1 study
Setting: not reported; assumed Jerusalem, Israel.
Funding: Teva GTC.
Participants Inclusion criteria:
• children aged 8-18 years with TBI who had spasticity “that interferes with task
performance;”
• documented loss of consciousness for > 24 hours or initial GCS < 8;
• able to co-operate and understand general explanations.
Exclusion criteria:
• history of allergy to tizanidine or any inactive component (including lactose
intolerance);
• use of other hypnotic medication within 3 days of baseline visit and during study;
• botulinum toxin A therapy within 6 weeks of baseline, or use of baclofen pump
during trial;
• use of CYP1A2 inhibitors (e.g. ciprofloxacin or fluvoxamine) for duration of
study;
• girls taking oral contraceptives;
• significant abnormalities in clinical screening laboratory parameters (alanine
transaminase, aspartate aminotransferase, bilirubin > 2 x upper limit of normal;
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creatinine > 2 mg/dL; white blood cell count < 2300/mm3 , platelets < 80,000/mm3);
• taking other medications that may have adversely interfered with actions of study
medication or outcome variables within 2 weeks or 5 half-lives of the baseline visit
Location of spasticity: not reported.
Interventions Intervention: tizanidine hydrochloride (administered sublingually)
Comparison: placebo.
Outcomes Primary outcomes:
• improvement in spasticity, cognition and daily function at 4 weeks.
Secondary outcomes:
• improvement in night-time sleep parameters as measured by actigraphy at 4 weeks.
Notes Communication with authors: this was a pilot conducted in the Alyn Rehabilitation
Hospital in Jerusalem. They reported the pilot yielded negative results, was not continued
and that none of the results were published
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not de-
scribed.
Allocation concealment (selection bias) Unclear risk Allocation concealment method not de-
scribed.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study described as “double blind” but
whether both participants and personnel
were blinded was unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Study described as “double blind” but
whether outcome assessors were blinded
was unclear
Incomplete outcome data (attrition bias) Unclear risk Withdrawals and loss to follow-up not de-
scribed.
Selective reporting (reporting bias) High risk Trial data “negative” as reported by authors,
and no available data; unpublished
Baseline Imbalances Unclear risk No information about participant demo-
graphics.
Appropriate study design (cross-over trial
only)
Unclear risk Not reported.
Adequate washout period (cross-over trial
only)
Unclear risk Not reported.
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Other bias Unclear risk Inadequate information to make a judge-
ment.
Pittaccio 2013
Methods Randomised cross-over trial.
Setting: Italy (at the Istituro Eugenio Media).
Funding: Fondazione Cariplo (Philanthropic organisation).
Participants Total participants: 25 overall study, including 16 with TBI (72% male in overall study)
Overall participants (TBI not reported separately): age: 7.75 years (SD 5.40, range 4-
19). However, the review author team calculated this (using the individual participant
ages provided in the paper and, which resulted in a mean age of 9.08 years (SD 5.38))
Adults: 0, children: 16.
Inclusion criteria:
• acquired quadriplegia or hemiplegia;
• aged 4-18 years;
• Ashworth Score for the target limb > 1.
Exclusion criteria:
• pathologies of the target joint or skin affections in the target area.
Location of spasticity:
upper limb: elbow (flexors);
lower limb: ankle (extensors).
Interventions Pseudoelastic orthosis: spring-loaded orthosis comprised of 2 parts that could rotate
relative to one another around a common axis. Each orthosis was individually customised
and worn for 1 month
Traditional static splint: no further details provided about the splint, other than it was
worn for 1 month
Washout period: no washout period as study authors considered it unethical to leave
participants without any treatment
Outcomes Outcome assessed at: baseline, and 1 (at cross-over) and 2 months (end of second treat-
ment)
Unclear which were primary and secondary outcomes
• range of motion;
• spasticity: Modified Ashworth Scale.
Length of follow-up: 2 months.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail on method of randomisation re-
ported.
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Allocation concealment (selection bias) Unclear risk No details on method of allocation con-
cealment (if any).
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding within this study was impossible
due to the nature of the 2 active treatments
(traditional splints appear very different to
the experimental ’pseudoelastic’ ones)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above. In addition, no attempts to
blind outcome assessors or data analysts to
the treatment status of participants was re-
ported
Incomplete outcome data (attrition bias) Low risk Appeared that all participants completed
treatment as intended and that there were
no missing data
Selective reporting (reporting bias) High risk No published protocol. Furthermore, there
was a pronounced tendency in the paper to
report perceived benefits in detail (e.g. data
regarding rigidity outcomes for ankles in
particular)whilst fewdetails andnonumer-
ical data were provided for results wherein
no difference between treated groups was
apparent (e.g. for spasticity as measured by
theModified Ashworth Scale) despite these
being collected after both treatment phases
as well as at baseline. Whilst this does not
indicate ’suppression’ of data, it obviates
meta-analyses (should comparable trials be
identified)
Baseline Imbalances Low risk Baseline imbalances not clear but not rele-
vant for a cross-over trial
Appropriate study design (cross-over trial
only)
Low risk A cross-over study design was reasonable
due to a small sample size
Adequate washout period (cross-over trial
only)
Low risk Investigators considered it unethical to
have a washout period; investigators also
went to lengths to confirm that the sequen-
tial order of treatments did not make any
difference to the final outcome (p = 0.30,
T2-T0, TP vs PT, paired 2-tailed Student’s
t test, 23 participants)
Other bias Unclear risk Although the inclusion criteria stated that
participants had to be aged 4-18 years and
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have a score > 1 on the Modified Ashworth
Scale, 1 participant was 19 years of age and
had a score of 0
Verplancke 2005
Methods Randomised controlled trial.
Setting: acute general hospital in the UK.
Funding: Allergan Inc. and 3M Health Care Ltd.
Participants Total participants: 35, 71% male, including 20 participants with TBI
Adults: 35, children 0.
Serial casting + botulinum toxin A 200 U: total 12 participants, median age 41.5 years;
TBI 6 participants
Serial casting + placebo (saline): total 12 participants, median age 33.5 years; TBI 6
participants
Control (physiotherapy): total 11 participants, median age 40 years; TBI 8 participants
Inclusion criteria:
• participants were screened twice weekly for 4 weeks and their passive range of
ankle dorsiflexion was measured in a supine position by a goniometer attached to a
multi-myometer and pressure strain gauge device (MIE Medical Research, Leeds, UK)
at a force of 65 N and by the same person, who documented the higher of 2 joint range
measurements;
• unable to achieve 3 degrees of passive ankle dorsiflexion at 65 N of force.
Exclusion criteria:
• pregnant;
• history of deep vein thrombosis within the previous 12 months;
• severe lower limb injury or lower limb fracture;
• previous exposure to continuous muscle relaxants;
• hypersensitivity to botulinum toxin;
• received botulinum toxin injections within the previous 3 months.
Location of spasticity:
lower limb: gastrocnemius and soleus.
The authors did not report if the participants had bilateral or unilateral symptoms
Interventions Physiotherapy (control): standard programme of physiotherapy, as currently practiced
in the neurosciences unit, but were not supplied with sheepskin bootees
Casting and placebo: lower leg casting plus injections with saline into gastrocnemius and
soleus muscles, those in casting and placebo were injected with 0.5 mL 0.9% normal
saline into each of 4 standard points into gastrocnemius and soleus muscles, giving a
total of 4 mL. They were additionally placed in a bespoke ’combicast’ made up of Soft
Cast and Scotchcast Plus (supplied by 3MHealth Care Ltd, Loughborough, UK), which
held the lower leg and foot in a neutral plantargrade position, but still allowed soft tissue
functioning within the rest of the limb
Casting and botulinum toxin A: lower leg casting + injections with botulinum toxin
A into gastrocnemius and soleus muscles. These participants were placed in casts in the
same way as for casting and placebo participants, but were additionally given an injection
of botulinum toxin A 200 U (Allergan Pharmaceuticals Inc., Irvine, CA, USA) per leg,
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equally divided into gastrocnemius and soleus muscles. Each 100-U vial of botulinum
toxin A was diluted
Outcomes Outcome assessed at: baseline and 12 weeks.
Primary outcomes:
• spasticity: Modified Ashworth Scale;
• adverse effect: not listed as an outcome measure, but was reported in the results
section.
Secondary outcomes:
• range of movement (ankle);
• Glasgow Outcome Scale;
• Glasgow Coma Scale.
Length of follow-up: not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were enrolled in a strict numeric
order, but the treatments were randomised
in groups of three (i.e., block randomisa-
tion in groups of three).”
Allocation concealment (selection bias) Unclear risk No Information provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “This ensured that blinding of the active
(casting +/- botulinum toxin A) treatments
still occurred and that recruitment pro-
duced an even spread of patients within the
groups. Blinding the assessor was not possi-
ble for control (physiotherapy) patients, as
they were not cast. Those treating patients
were also blinded.” The authors attempted
to blind the personnel; however, this was
impossible due to some participants not re-
ceiving a cast
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The observer was blinded between the ac-
tive groups, but the absence of a cast in con-
trol patients may have biased the findings.
This is actually unlikely, as the primary out-
come measure was a quantifiable number
at a given force and previous data were not
available to the assessor for comparison un-
til all the measurements were carried out.”
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Incomplete outcome data (attrition bias) Unclear risk 4 participants were withdrawn from the
study but it was not reported which groups
they from.However, the final measure used
in these participants was the 1 taken prior
to their exclusion
“In order to prevent fixed contracture for-
mation, patients were withdrawn from the
study if they became unable to dorsiflex
to > -10 degrees. At the time it was con-
sidered unethical to continue without us-
ing botulinum toxin A and/or casting, and
rescue treatment was administered (bo-
tulinum toxin injections for groups con-
trols and cast and saline and normal saline
injections for cast and botulinum toxin pa-
tients). As the assessor continued to be
blinded to treatment after rescue treatment
was administered, assessment of patients’
spasticity continued, but the final measure-
ment prior to exclusion was used for statis-
tical analysis.”
Selective reporting (reporting bias) High risk All outcomes were reported but no pub-
lished protocol. No baseline data for the
primary outcome (ankle dorsiflexion). No
between-group comparisons for the sec-
ondary outcomes
Baseline Imbalances Unclear risk “...patients in the three groups were suf-
ficiently uniform in their characteristics;”
however, the authors later stated that, “The
patients in all the groups were similar in
most respects, but control patients had the
smallest range of dorsiflexion at entry and
exit.”
Appropriate study design (cross-over trial
only)
Low risk Not relevant, not a cross-over trial.
Adequate washout period (cross-over trial
only)
Low risk Not relevant, not a cross-over trial.
Other bias Low risk No concerns noted.
EQ-5D: EuroQol; FIM: Functional Independence Measure; ITT: intention to treat; SD: standard deviation; SF-36: 36-item Short
Form; TBI: traumatic brain injury.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armstrong 1997 Number of TBI participants < 50% threshold. Total 19 participants, TBI 2 participants
Ashby 1972 Number of TBI participants < 50% threshold. Total 15 participants, TBI 4 participants
Baricich 2008 All participants had had a stroke.
Barnes 2010 Number of TBI participants < 50% threshold. Total 192 participants, TBI 11 participants
Basmajian 1973 All participants had multiple sclerosis, spinal cord injury, dermoid cyst or meningioma
Basmajian 1974 All participants had multiple sclerosis, spinal cord injury, demyelinating spinal cord disease or congenital
quadriplegia
Bensmail 2010 Control group not affected by spasticity and there was no randomisation
Bes 1988 No valid measure for spasticity
Bovend’Eerdt 2009 Unable to identify if brain injured participants were due to trauma
Boyd 2001 All participants had cerebral palsy.
Burbaud 1996 Number of TBI participants < 50% threshold. Total 23 participants, TBI 4 participants
Burke 1975 Number of TBI participants < 50% threshold. Total 9 participants, TBI 2 participants
Chang 2009 Number of TBI participants < 50% threshold. Total 14 participants, TBI 3 participants
Childers 1996 Number of TBI participants < 50% threshold. Total 17 participants, TBI 2 participants
Cocchiarella 1967 All participants had cerebrovascular accident, cervical spondylosis or demyelinating disease
Cohan 1980 All participants had multiple sclerosis, infarction of the anterior thoracic spinal cord, degeneration of the
spinal cord, cerebral palsy, amyotrophic lateral sclerosis or cervical spondylosis
Copley 2013 Number of TBI participants < 50% threshold. Total 10 participants, TBI 2 participants
Corry 1998 All participants had cerebral palsy.
Fazekas 2007 Number of TBI participants < 50% threshold. Total 30 participants, TBI 8 participants
Fietzek 2014 Number of TBI participants < 50% threshold. Total 52 participants, TBI 6 participants
Francisco 2002 Number of TBI participants < 50% threshold. Total 13 participants, TBI 3 participants
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(Continued)
Gracies 2009 Number of TBI participants < 50% threshold. Total 21 participants, TBI 6 participants
Grazko 1995 Number of TBI participants < 50% threshold. Total 20 participants, TBI 1 participants
Guo 2006 Number of TBI participants < 50% threshold. Total 60 participants, TBI 17 participants
Harvey 1974 No information could be obtained to clarify if any participants had a TBI
Harvey 2006 Number of TBI participants < 50% threshold. Total 44 participants, TBI 7 participants
Hill 1994 No valid measure for spasticity.
Imle 1986 No control/placebo comparison group.
Krewer 2014 Number of TBI participants < 50% threshold. Total 66 participants, TBI 3 participants
Lannin 2003 Number of TBI participants < 50% threshold. Total 28 participants, TBI 2 participants
Leung 2012 Majority of participants had stroke, not TBI.
Levine 1969 All participants had multiple sclerosis.
Levine 1977 All participants had multiple sclerosis or spinal cord injury
Mancini 2005 All participants had stroke.
Martin 2014 Not an RCT (a systematic review).
Mayer 2008 Compared botulinum toxin A injection technique; motor point vs quadrant
McPherson 1982 No valid measure for spasticity.
Meythaler 2001b Number of TBI participants < 50% threshold. Total 17 participants, TBI 8 participants
Middel 1997 All participants had multiple sclerosis or spinal cord injury
Moseley 1997 Spasticity not an outcome measure.
Moseley 2008 Did not report whether the participants had spasticity.
Nakhostin 2009 Number of TBI participants < 50% threshold. Total 21 participants, TBI 1 participants
NCT00776048 Observational study.
NCT00900666 Included < 50% people with TBI.
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(Continued)
Pagano 1990 All participants had multiple sclerosis, myelopathy, cerebrovascular accident or perinatal encephalopathy
Penn 1988 It is unclear if the study included people with TBI, but would appear that it solely included people with
spinal cord injury or multiple sclerosis
Richardson 2000 Unable to identify if the 12 brain-injured participants had experiences trauma
Roussan 1985 All participants had multiple sclerosis, traumatic paraplegia or transverse myelopathy
Sahuquillo 2000 Participants with cerebral vasospasms.
Simpson 1996 Participants had stroke.
Simpson 2009 Number of TBI participants < 50% threshold. Total 60 participants, TBI 11 participants
Smith 2000 Number of TBI participants < 50% threshold. Total 21 participants, TBI 2 participants
Snow 1990 All participants had multiple sclerosis.
Suputtitada 2005 All participants had stroke.
Thibaut 2015 Number of TBI participants < 50% threshold. Total 17 participants, TBI 7 participants
Van Schaeybroeck 2000 Number of TBI participants < 50% threshold. Total 1 participant, TBI 1 participant
Yelnik 2007 All participants had stroke.
Zhao 2015 Number of TBI participants < 50% threshold. Total 60 participants, TBI 1 participant
RCT: randomised controlled trial; TBI: traumatic brain injury.
Characteristics of studies awaiting assessment [ordered by study ID]
2009-015868-34
Methods Randomised controlled trial (completed).
Setting: European sites (multiple), Russia, US.
Funding: Ipsen Pharma SAS.
Participants 348 people with hemiparesis with lower limb spasticity due to stroke or TBI (unclear what percentage had a TBI)
Interventions Intervention: Dysport (abobotulinumtoxinA) intramuscular injection 500 U/mL
Comparator: placebo (no further information provided).
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2009-015868-34 (Continued)
Outcomes Outcome assessed at: baseline, 4 weeks
Primary outcomes:
• spasticity (Modified Ashworth Scale) change from baseline in the gastrocnemius-soleus complex muscle tone
(knee extended).
Secondary outcomes:
• mean Physician’s Global Assessment Score;
• mean change from baseline in comfortable barefoot walking speed without walking aids.
Notes Results are unpublished and it states on the clinical trials registry site: “Results removed from public view.” Contacted
study sponsor in April 2017 seeking further information about results for participants with TBI but no further
information received
EUCTR2011-005375-16-SE
Methods Randomised controlled trial (completed).
Setting: Norway, Sweden, Denmark, Finland.
Funding: Institut Produits Synthèse (IPSEN) AB.
Participants 88 participants, with upper limb spasticity due to stroke or TBI (unclear what percentage had a TBI)
Interventions Intervention: low-concentrationdilution (100U/mL)Dysport (abobotulinumtoxinA) injected via the neuromuscular
junction targeted technique
Comparison: high-concentration dilution (300 U/mL) Dysport (abobotulinumtoxinA) injected via “current clinical
practice technique.”
Outcomes Outcomes measured as change from baseline at 4 and 12 weeks post-treatment
Primary outcomes:
• spasticity (Modified Ashworth Scale);
• adverse events.
Secondary outcomes:
• pain (spasticity related pain measured by visual analogue scale);
• Global Attainment Scale.
Notes Results available on the EUClinical Trials Register site but the results for people with TBI are not presented separately,
and it is unclear what percentage of participants had a brain injury. The authors reported that “Due to slow recruitment
rate it was clear that the study would not be completed in a reasonable time frame, therefore the study was stopped
early.” Contacted study sponsor in April 2017 but no further information received
Gracies 2016
Methods 3-arm randomised controlled trial (completed).
Setting: US, Australia, Belgium, Czech Republic, France, Hungary, Italy, Poland, Portugal, Russian Federation,
Slovakia
Funding: Ipsen.
Participants 388 participants with stroke or TBI with lower limb spasticity. While the number of participants with TBI was not
reported, a poster presented on the results of the follow-up open-label study (see Notes) reported 43/352 participants
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Gracies 2016 (Continued)
with TBI
Interventions Intervention: abobotulinumtoxinA 1000 U, 1 cycle.
Intervention: abobotulinumtoxinA 1500 U, 1 cycle.
Control: “placebo”, 1 cycle.
Outcomes Outcomes measured at 4 weeks.
Primary outcomes:
• spasticity in gastrocnemius/soleus muscles (Modified Ashworth Scale);
• adverse event.
Notes Found a protocol (see reference list) and a poster on ResearchGate, which describes the results for the follow-up open-
label study. While the number of participants with TBI would appear to be below 50% the authors may subsequently
publish, or be able to provide, the data for participants with TBI only
IRCT2014041112777N
Methods Randomised controlled trial (complete).
Setting: Iran.
Funding: Ahvaz Jundishapur University of Medical Sciences
Participants 40 participants with diffuse axonal injury without chronic hepatic or renal disease; aged 15-60 years
Interventions Intervention: oral cyproheptadine 2 mg/kg with oral baclofen 25 mg/kg every 8 hours for 15 days
Comparison: oral baclofen 25 mg/kg every 8 hours for 15 days
Outcomes Primary outcome:
• spasticity (Modified Ashworth Scale) at days 1, 3, 6, 9, 12 and 15.
Notes The clinical trial entry stated that, “patients will be randomly allocated into two groups according to table of random
numbers” and that the trial is complete (recruitment was expected to end in December 2014). We found a published
paper by the same investigators (Rasras 2014) also treating spasticity in people with TBI with considerable overlap
(i.e. identical inclusion criteria) but with somewhat different interventions (baclofen, cyproheptadine + baclofen,
baclofen + tizanidine + baclofen, and cyproheptadine + tizanidine). We noted that the randomisation procedure in
this trial did not appear to be truly random. It was described as follows: “the first to third patients were randomly
placed in the first to third groups. The next patients were distributed successfully within the groups with respect to
their registration in the ward. This was continued until the sample size reached the required number.” We contacted
the trialists in August 2017 to clarify if the protocol and published paper were the same study but received no reply
NCT02052024
Methods Randomised controlled trial (complete; final data collection August 2015)
Setting: US.
Funding: Georgetown University (Solstice Neurosciences, a pharmaceutical company, listed as a collaborator)
Participants People aged ≥ 18 years with spasticity due to a disorder or trauma (e.g. spinal cord injury, brain injury, tumour,
stroke, multiple sclerosis or peripheral nerve injury)
61Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02052024 (Continued)
Interventions Intervention: botulinum toxin A (Botox), 100 U per injection, 1-3 injections per muscle at each visit
Comparator: botulinum toxin B (Myobloc), 5000 U per injection, 1-3 injections per muscle at each visit
Number of visits per week not reported but treatment administered for 36 weeks
Outcomes Primary outcomes:
• adverse events (muscle atrophy, measured by volume and cross-sectional area of muscle) at 36 weeks;
• spasticity (Modified Ashworth Scale), measured before, during and after treatment at every visit, up to 36
weeks.
Notes We are unable to find any published results for this trial. As such, it was unclear what percentage of participants had
TBI, or whether the results for this group is (or could be) presented separately
TBI: traumatic brain injury.
Characteristics of ongoing studies [ordered by study ID]
ACTRN12615000821594
Trial name or title Effectiveness of Combining Serial Casting and Botulinum Toxin for the Management of Ankle Contractures
after Traumatic Brain Injury: a Randomised Controlled Study
Methods Randomised controlled trial (2 arms, with cross-over).
Setting: Brain Injury Unit, Sydney, Australia.
Funding: Royal Rehab Foundation (charitable).
Participants Total participants: 10 (anticipated).
Age range: 18-85 years.
Inclusion criteria:
• diagnosed with first TBI;
• presents with an ankle contracture of a severe degree;
• able to receive botulinum toxin injections and serial casting;
• unlikely to be discharged in 12 weeks; and
• provides consent to participate in the study (the participants or the person legally responsible for them).
Exclusion criteria:
• unstable medical conditions or recent ankle fracture;
• within 3 months after receiving botulinum toxin;
• severe ankle varus or knee/hip flexion contractures (which affects the reliability of measuring ankle
dorsiflexion).
Location of spasticity:
Calf muscles/ankle. Specific muscles that may be treated include soleus, gastrocnemius, flexor hallucis longer
and flexor digitorium longus and tibialis posterior where necessary
Interventions Botulinum toxin and serial casting: ≥ 1 botulinum toxin injections into calf muscles (dose dependent on
number of muscles needing injection, but not in excess of 400 mL). Serial casting with be commenced within
a few days (duration of casting and number of cast applied may vary based on the participants’ responses to
casting), After completion of casting, a customised ankle splint will be used immediately. The splint will be
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ACTRN12615000821594 (Continued)
worn 24 hours a day for the initial 2 weeks during which the splint will only be removed for hygiene reasons
and therapy. Participants will receive usual care as well (see usual care)
Usual care: placed on a wait list for 6 weeks during which they receive no botulinum toxin, splinting and
passive stretch-based interventions for the ankle. Usual care includes multidisciplinary rehabilitation provided
by the unit as appropriate. This consisted of physiotherapy, occupational therapy, speech therapy, recreational
therapy andpsychological therapy. Physiotherapy included an individualisedmotor trainingprogrammewhich
might involve lower limb exercises, practice of sit to stand, standing and walking. Also involves positioning
of participants’ feet in dorsiflexion while seated and lying
Outcomes Primary outcome:
• Passive dorsiflexion range at a standardised torque, measured within 3 days after completion of serial
casting.
Secondary outcomes:
• Spasticity of ankle plantarflexors (Tardieu Scale score and Modified Ashworth Scale score), measured
within 3 days after completion of serial casting;
• FIM Walking score and 10-m walk test, measured within 3 days after completion of serial casting;
• therapist questionnaire (perceived effectiveness, adverse events and treatment worth), designed
specifically for study.
Starting date 1 July 2015 (date of first participant enrolment).
Contact information Dr Joan Wai King Leung, Brain Injury Unit, Royal Rehab, Ryde, NSW. Email: joan.leung@royalrehab.com.
au
Notes Anticipated end date (as per clinical trials entry last updated in 13 July 2016): 1 September 2018
Note that spasticity is not an inclusion criterion, but as per the other study by this investigator (Leung 2014)
, spasticity is being measured at baseline, and is an outcome. In future updates, the review author team will
contact the lead investigator to determine how many of the participants had spasticity at baseline to therefore
confirm it meets the inclusion criteria for the review
FIM: Functional Independence Measure; TBI: traumatic brain injury.
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D A T A A N D A N A L Y S E S
Comparison 1. Casting plus botulinum toxin A versus casting plus placebo




participants Statistical method Effect size
1 Spasticity at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Casting plus botulinum toxin A versus physiotherapy




participants Statistical method Effect size
1 Spasticity at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Casting plus placebo versus physiotherapy




participants Statistical method Effect size
1 Spasticity at 12 weeks 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Tilt table plus electrical stimulation plus splint versus tilt table




participants Statistical method Effect size
1 Spasticity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Passive ankle dorsiflexion 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Walking speed 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Analysis 1.1. Comparison 1 Casting plus botulinum toxin A versus casting plus placebo, Outcome 1
Spasticity at 12 weeks.
Review: Interventions for managing skeletal muscle spasticity following traumatic brain injury
Comparison: 1 Casting plus botulinum toxin A versus casting plus placebo
Outcome: 1 Spasticity at 12 weeks





N Mean(SD)[points] N Mean(SD)[points] IV,Fixed,95% CI IV,Fixed,95% CI
Verplancke 2005 12 1.3 (1.619) 12 1 (1.297) 0.30 [ -0.87, 1.47 ]
-4 -2 0 2 4
Favours casting + botox Favours casting + placebo
Analysis 2.1. Comparison 2 Casting plus botulinum toxin A versus physiotherapy, Outcome 1 Spasticity at
12 weeks.
Review: Interventions for managing skeletal muscle spasticity following traumatic brain injury
Comparison: 2 Casting plus botulinum toxin A versus physiotherapy
Outcome: 1 Spasticity at 12 weeks





N Mean(SD)[points] N Mean(SD)[points] IV,Fixed,95% CI IV,Fixed,95% CI
Verplancke 2005 12 1.3 (1.619) 11 1.8 (1.602) -0.50 [ -1.82, 0.82 ]
-4 -2 0 2 4
Favours casting + botox Favours physiotherapy
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Analysis 3.1. Comparison 3 Casting plus placebo versus physiotherapy, Outcome 1 Spasticity at 12 weeks.
Review: Interventions for managing skeletal muscle spasticity following traumatic brain injury
Comparison: 3 Casting plus placebo versus physiotherapy
Outcome: 1 Spasticity at 12 weeks





N Mean(SD)[points] N Mean(SD)[points] IV,Fixed,95% CI IV,Fixed,95% CI
Verplancke 2005 12 1 (1.297) 11 1.8 (1.602) -0.80 [ -2.00, 0.40 ]
-4 -2 0 2 4
Favours casting + placebo Favours physiotherapy
Analysis 4.1. Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 1
Spasticity.
Review: Interventions for managing skeletal muscle spasticity following traumatic brain injury
Comparison: 4 Tilt table plus electrical stimulation plus splint versus tilt table
Outcome: 1 Spasticity





N Mean(SD)[points] N Mean(SD)[points] IV,Fixed,95% CI IV,Fixed,95% CI
Leung 2014 (1) 17 2 (1) 18 3 (1) -1.00 [ -1.66, -0.34 ]
Leung 2014 (2) 17 3 (1) 15 2 (1) 1.00 [ 0.31, 1.69 ]
-2 -1 0 1 2
Favours tilt table ’plus’ Favours tilt table
(1) Measured at six weeks
(2) Measured at 10 weeks.
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Analysis 4.2. Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 2
Passive ankle dorsiflexion.
Review: Interventions for managing skeletal muscle spasticity following traumatic brain injury
Comparison: 4 Tilt table plus electrical stimulation plus splint versus tilt table
Outcome: 2 Passive ankle dorsiflexion





N Mean(SD)[degrees] N Mean(SD)[degrees] IV,Fixed,95% CI IV,Fixed,95% CI
Leung 2014 (1) 16 -2 (5) 15 -3 (7) 1.00 [ -3.31, 5.31 ]
Leung 2014 (2) 16 -5 (6) 17 -3 (9) -2.00 [ -7.19, 3.19 ]
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours tilt table Favours tilt table ’plus’
(1) Measured at 10 weeks.
(2) Measured at six weeks.
Analysis 4.3. Comparison 4 Tilt table plus electrical stimulation plus splint versus tilt table, Outcome 3
Walking speed.
Review: Interventions for managing skeletal muscle spasticity following traumatic brain injury
Comparison: 4 Tilt table plus electrical stimulation plus splint versus tilt table
Outcome: 3 Walking speed





N Mean(SD)[m/second] N Mean(SD)[m/second] IV,Fixed,95% CI IV,Fixed,95% CI
Leung 2014 (1) 17 0.3 (0.5) 18 0.4 (0.5) -0.10 [ -0.43, 0.23 ]
Leung 2014 (2) 17 0.4 (0.6) 15 0.4 (0.5) 0.0 [ -0.38, 0.38 ]
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours tilt table ’plus’ Favours tilt table
(1) Measured at six weeks.
(2) Measured at 10 weeks.
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A D D I T I O N A L T A B L E S
Table 1. Excluded studies with less than 50% of participants with traumatic brain injury
Author (year) n total n TBI % TBI Intervention Comparator %TBI
Intervention
%TBI comparator
Botulinum toxin A vs placebo
NCT00900666
19 7 37 Botulinum toxin A Placebo NR NR
Burbaud 1996 23 4 17 Botulinum toxin A Placebo NR NR
Fietzek 2014 52 6 12 Botulinum toxin A Placebo 12 12
Grazko 1995 20 1 5 Botulinum toxin A Placebo Cross-over trial -
Simpson 2009 60 11 18 Botulinum toxin A Tizanidine or
placebo
15 14 and 26 placebo
Smith 2000 21 2 10 Botulinum toxin A Placebo 10 16
Botulinum toxin A vs therapy
Guo 2006 60 17 28 Botulinum toxin A
with rehab
Rehab only 26 30
Botulinum toxin A vs botulinum toxin A (dosage)





with end plate tar-
get
NR NR
Botulinum toxin A vs botulinum toxin A (volume)
Francisco
2002










Botulinum toxin A vs botulinum toxin A (location)












with end plate tar-
NR NR
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11 1 9 Intrathecal baclofen Placebo 16 0
Cyclobenzaprine vs placebo
Ashby 1972 15 4 27 Cyclobenzaprine Placebo Cross-over trial -
Phenothiazine vs placebo




17 8 47 Tizanidine Placebo Cross-over trial -
Tizanidine vs botulinum toxin A
Simpson 2009 60 11 18 Botulinum toxin A Tizanidine or
placebo
15 14 and 26 placebo
Tizanidine vs diazepam
Bes 1988 105 16 15 Tizanidine Diazepam 10 20
Casting vs control
Harvey 2006 44 7 16 Splint No splint 13 21
Casting vs therapy
Harvey 2006 44 7 16 Splint No splint 13 21
Splinting vs control
Copley 2013 10 2 20 Individualised hand
splint
No splint 33 0
Lannin 2003 28 2 7 Stretching and
hand splint
Stretching only NR NR
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Table 1. Excluded studies with less than 50% of participants with traumatic brain injury (Continued)
Thibaut 2015 17 7 41 Soft splints No treatment NR NR
Splinting vs therapy
Lannin 2003 28 2 7 Stretching and
hand splint
Stretching only NR NR
Thibaut 2015 17 7 41 Soft splints Stretching NR NR
Functional electrical stimulation vs control
Chang 2009 14 3 21 Upper limb bo-








Electrical stimulation + splinting vs splinting
Leung 2012 36 5 14 Electrical stimula-
tion to the wrist
and finger extensor
muscles for 1 hour
a day + wrist splint
for 12 hours a day,
over 4 weeks
Wrist splint for 12
hours a day, over 4
weeks
6 22
Repetitive peripheral magnetic stimulation vs sham
Krewer 2014 66 3 5 Repetitive periph-
eral magnetic stim-
ulation
Sham stimulation 10 0
Transcutaneous electrical acupoint stimulation vs another dose









Transcutaneous electrical acupoint stimulation vs sham




Sham stimulation 0 0
Ultrasound vs infrared
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Table 1. Excluded studies with less than 50% of participants with traumatic brain injury (Continued)
Nakhostin
2009




Fazekas 2007 30 8 27 Robot-me-
diated therapy with
bobath therapy
Bobath therapy 13 40
n: number of participants; NR: not reported; TBI: traumatic brain injury.
Some studies are listed in the table twice, given their multiple comparisons.
Table 2. Primary outcome measures
Outcome measure Domains with score Studies referring to this out-
come
Time point analysis
Ashworth Scale (0-4, lower
score = better; Pandyan 1999)
0: no increase in muscle tone.
1: slight increase inmuscle tone,
manifested by a catch and re-
lease or by minimum resistance
through remainder of range of
motion
2: more marked increase in
muscle tone through most of
the range of motion; limb easily
moved
3: considerable increase in mus-
cle tone; passive movement is
difficult
4: rigid limb.
Meythaler 1996; Baseline, and 1, 2, 4, 6 hours
Pittaccio 2013 Baseline, and 4, 8 weeks
Modified Ashworth Scale (0-5,
lower score = better; Pandyan
1999)
0: no increase in muscle tone.
1: slight increase inmuscle tone,
manifested by a catch and re-
lease or is moved in flexion, ex-
tension/abduction, adduction,
etc
1+: slight increase in muscle
tone, manifested by a catch,
followed by minimal resistance
throughout the remainder (less
than half ) of the range of mo-
tion
2: More marked increase in
muscle tone through most of
the range of motion, but the af-
Verplancke 2005 Baseline, 12 weeks
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Table 2. Primary outcome measures (Continued)
fected part is easily moved
3: considerable increase in mus-
cle tone, passive movement is
difficult
4: affected part is rigid flexionor
extension/abduction or adduc-
tion Gracies 2015 Baseline, 4 weeks
Tardieu Scale (TS; 2 measure-
ments: Quality of Muscle Reac-
tion 0-4, lower score better, and
Angle of muscle reaction, R2 -
R1; Haugh 2006)
Quality of muscle reaction
0: no resistance throughout the
course of the passive movement
1: slight resistance throughout
the course of the passive move-
ment, with no clear catch at pre-
cise angle
2: clear catch at precise angle,
interrupting the passive move-
ment, followed by release
3: fatigable clonus (< 10 seconds
whenmaintaining pressure) oc-
curring at precise angle
4: infatigable clonus (> 10 sec-
onds when maintaining pres-
sure) occurring at precise angle
Angle of muscle reaction (also
referred to as R2 - R1)
Measured relative to the posi-
tion of minimal stretch of the
muscle (corresponding to an-
gle) where it is relative to the
resting anatomic position
R2: first measure (the maxi-
mum passive range of move-
ment of the muscle group)
R1: second measure (the angle
at which the initial ’catch’ or
muscle resistance is felt when
the muscle is moved from its
shortest to longest position us-
ing a ’rapid velocity stretch’)
Gracies 2015 Baseline, 4 weeks
Leung 2014 Baseline, and 6 and 10 weeks
Table 3. Secondary outcome measures
Outcome measure Domains with score Studies referring to this out-
come
ICF classification
72Interventions for managing skeletal muscle spasticity following traumatic brain injury (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Secondary outcome measures (Continued)
Glasgow Coma Scale (Teasdale
1974)









3: words, but not coherent




5: localised to pain
4: withdraws to pain
3: decorticate posture (an ab-
normal posture that can include
rigidity, clenched fists, legs held
straight out, and arms bent in-
ward towards the body with the
wrists and fingers bend and held
on the chest)
2: decerebrate (an abnormal
posture that can include rigid-
ity, arms and legs held straight
out, toes pointed downward,
head and neck arched back-
wards)
1: none
The final GCS score or grade is
the sum of these numbers.
Severe: GCS 3-8 (minimum
possible score is 3)
Moderate: GCS 9-12
Mild: GCS 13-15
Verplancke 2005 b. Body functions
b1-b8
Glasgow Outcome Scale (
Jennett 1975)
(1-5, higher score = better)
To generalise and categorise the
outcomes of people with TBI
1: dead
2: vegetative state (meaning
the person is unresponsive, but
alive; a “vegetable” in lay lan-
guage)
3: severely disabled (conscious
but the person requires others
for daily support due to disabil-
ity)
4: moderately disabled (the per-
son is independent but dis-
Verplancke 2005 Body function
b1-b8
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Table 3. Secondary outcome measures (Continued)
abled)
5: good recovery (the person has
resumed most normal activities
but may have minor residual
problems)
Range of movement The joint is taken through the
total arc of movement from
flexion to extension
Verplancke 2005 (ankle) Body function
b7




4: 3 or 4 beats clonus only
5: clonus
Meythaler 1996 Body function
b750
Disability Assessment
Scale (DAS; Brashear 2002; 0-
3, lower score better)
People are interviewed to deter-
mine the extent of functional
impairment in: hygiene, dress-
ing, limb position and pain, ac-
cording to the following scale:
0: no disability
1: mild disability (noticeable
but does not interfere signifi-
cantly with normal activities)
2: moderate disability (normal
activities require increased ef-
fort or assistance, or both)
3: severe disability (normal ac-
tivities limited)
Gracies 2015 Activities and participation
ICF: International Classification of Functioning.
Table 4. Adverse effects
Adverse effect Number of participants affected Studies
Deep vein thrombosis 1 participants withdrawn from physiother-
apy group.
Verplancke 2005
Contracture at subtalar joint 1 participants withdrawn from the casting
+ placebo group.
Verplancke 2005
No adverse events or changes in alertness
level were observed in the baclofen group
or placebo arm
Not applicable. Meythaler 1996
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Table 4. Adverse effects (Continued)
Unspecified “treatment emergent AE [ad-
verse effects]”: “none were unexpected”
7/23 participants, no other information
given.
Gracies 2015 (O’Dell 2015)
Skin rashes/oedema/tolerability issues No pseudoelastic device required adjust-
ment for comfort; 30% of traditional de-
vices did. Families reportednovel treatment
tolerated for 40% longer than traditional
(Pittaccio 2013).
2 participants adherence to splinting was
affected by ’skin problems’ and ’poor toler-
ance’ (Leung 2014).
50% of participants in casting group and
41.7% of participants in casting + bo-
tulinum toxin A group developed ’minor
skin damage’. Overall, 90% of those re-
solved spontaneously or with therapeutic
dressing (Verplancke 2005).
Leung 2014; Pittaccio 2013; Verplancke
2005
Fainting, fatigue, storming1 Several participants’ adherence to the tilt
table was affected due to fainting, fatigue
and storming
Leung 2014
1When someone with a head injury responds to a sensation with a tonic posture or sympathetic response.
A P P E N D I C E S
Appendix 1. 2016 Search strategies
Cochrane Injuries Group Specialised Register
(spastic* or spasm*) or ((muscle* or muscular) and (spasm* or cramp* or
clonus or hypertoni* or overact*))
MEDLINE (OvidSP)
1. exp Brain Injuries/
2. exp Craniocerebral Trauma/
3. exp Brain Edema/
4. exp Glasgow Coma Scale/
5. exp Glasgow Outcome Scale/
6. exp Unconsciousness/
7. exp Cerebrovascular Trauma/
8. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or
trauma* or lesion* or damag* or wound* or destruction* or oedema* or edema* or fractur* or contusion* or concus* or commotion*
or pressur*)).ti,ab. (108776)
9. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)).ti,ab.
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10. (Glasgow adj3 scale).ti,ab.
11. “rancho los amigos scale”.ti,ab.
12. (“diffuse axonal injury” or “diffuse axonal injuries”).ti,ab.
13. “persistent vegetative state”.ti,ab.
14. ((unconscious* or coma* or concuss*) adj3 (injur* or trauma* or damag* or wound* or fracture* or contusion* or haematoma* or





19. (spastic* or spasm*).ti,ab.
20. ((muscle* or muscular) adj3 (spasm* or cramp* or clonus or hypertoni* or overact*)).ti,ab.
21.16 or 17 or 18 or 19 or 20
22. randomised controlled trial.pt.







30. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. exp animals/ not humans.sh.
32. 30 not 31
33. 15 and 21 and 32
Embase Classic + Embase (OvidSP)
1. exp Brain Injuries/
2. exp Brain Edema/
3. exp Craniocerebral Trauma/
4. exp Glasgow Coma Scale/
5. exp Glasgow Outcome Scale/
6. exp Unconsciousness/
7. exp Cerebrovascular Trauma/
8. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or
trauma* or lesion* or damag* or wound* or destruction* or oedema* or edema* or fractur* or contusion* or concus* or commotion*
or pressur*)).ti,ab.
9. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)).ti,ab.
10. (Glasgow adj3 scale).ti,ab.
11. “rancho los amigos scale”.ti,ab.
12. (“diffuse axonal injury” or “diffuse axonal injuries”).ti,ab.
13. “persistent vegetative state”.ti,ab.
14. ((unconscious* or coma* or concuss*) adj3 (injur* or trauma* or damag* or wound* or fracture* or contusion* or haematoma* or
hematoma* or haemorrhag* or hemorrhag* or bleed* or pressure)).ti,ab.
15. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. exp Muscle Spasticity/
17. exp Spasm/
18. exp Muscle Hypertonia/
19. (spastic* or spasm*).ti,ab.
20. ((muscle* or muscular) adj3 (spasm* or cramp* or clonus or hypertoni* or overact*)).ti,ab.
21. 16 or 17 or 18 or 19 or 20
22. 15 and 21
23. exp Randomized Controlled Trial/
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24. exp controlled clinical trial/





30. exp major clinical study/
31. randomly.ab.
32. (trial or study).ti.
33. 23 or 24 or 25 or 27 or 28 or 29 or 30 or 31 or 32
34. exp animal/ not (exp human/ and exp animal/)
35. 33 not 34
36. 22 and 35
Appendix 2. 2017 prepublication search strategies
Cochrane Injuries Group Specialised Register (SR-INJ) (all years to 22-June-2017)
(spastic* or spasm*) or ((muscle* or muscular) and (cramp* or
clonus or contractur* or hypertoni* or overact*)) [all fields] IN REGISTER
Ovid MEDLINE Databases
(Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 22-June-
2017)
1. exp Brain Injuries/
2. exp Craniocerebral Trauma/
3. exp Brain Edema/
4. exp Glasgow Coma Scale/
5. exp Glasgow Outcome Scale/
6. exp Unconsciousness/
7. exp Cerebrovascular Trauma/
8. ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or inter-cran*) adj3 (injur* or
trauma* or lesion* or damag* or wound* or destruction* or oedema* or edema* or fractur* or contusion* or concus* or commotion*
or pressur*)).ti,ab. (108776)
9. ((head or crani* or cerebr* or brain* or intra-cran* or inter-cran*) adj3 (haematoma* or hematoma* or haemorrhag* or hemorrhag*
or bleed* or pressure)).ti,ab.
10. (Glasgow adj3 scale).ti,ab.
11. “rancho los amigos scale”.ti,ab.
12. (“diffuse axonal injury” or “diffuse axonal injuries”).ti,ab.
13. “persistent vegetative state”.ti,ab.
14. ((unconscious* or coma* or concuss*) adj3 (injur* or trauma* or damag* or wound* or fracture* or contusion* or haematoma* or





19. (spastic* or spasm*).ti,ab.
20. ((muscle* or muscular) adj3 (spasm* or cramp* or clonus or hypertoni* or overact*)).ti,ab.
21.16 or 17 or 18 or 19 or 20
22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. (RCT or randomised or randomized).ab.
25. placebo.ab.
26. drug therapy.fs.
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30. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. exp animals/ not humans.sh.
32. 30 not 31
33. 15 and 21 and 32
The Cochrane Library, Central Register of Controlled Trials (CENTRAL), Issue 6, June 2017
#1 MeSH descriptor: [Brain Injuries] explode all trees
#2 MeSH descriptor: [Brain Damage, Chronic] explode all trees
#3 MeSH descriptor: [Head Injuries, Closed] explode all trees
#4 (TBI or mTBI or sTBI):ti,ab,kw (Word variations have been searched)
#5 “diffuse axonal injury”:ti,ab,kw (Word variations have been searched)
#6 ((head or brain or cerebr* or crani*) near (injur* or trauma*)):ti,ab,kw (Word variations have been searched)
#7 (#1 or #2 or #3 or #4 or #5 or #6)
#8 MeSH descriptor: [Muscle Hypertonia] explode all trees
#9 spastic* or spasm*:ti,ab,kw (Word variations have been searched)
#10 ((muscle* or muscular) near (spasm* or cramp* or clonus or contractur* or hypertoni* or overact*)):ti,ab,kw (Word variations have
been searched)
#11 (#8 or #9 or #10)
#12 (#7 and #11)
#13 ((cerebral palsy or stroke or post stroke) not ((head or brain) and (injur* or trauma*))):ti (Word variations have been searched)
#14 (#12 not #13)
NLM PubMed (22 June 2017)
Precision maximising search: ((randomised[tiab] OR randomized[tiab] OR placebo[tiab] OR trial[ti] OR randomized controlled
trial[pt]) AND (“Craniocerebral Trauma”[Mesh] OR TBI OR mTBI OR sTBI OR “brain injury” OR “brain injuries” OR “traumatic
brain” OR “brain trauma”) AND (“Muscle Spasticity”[MeSH] OR spastic[tiab] OR spasticity[tiab]) AND (publisher[sb] OR inpro-
cess[sb] OR pubmednotmedline[sb]))
Ovid Embase <1974 to 2017 Week 25>
1 randomized controlled trial/






8 ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask* or dummy)).ti,ab,kw.
9 double blind procedure/
10 (RCT or at random or (random* adj (assign* or allocat* or divid* or division or number))).ti,ab,kw.
11 trial.ti.
12 or/1-11
13 ((animal or nonhuman) not (human and (animal or nonhuman))).de.
14 12 not 13
15 head injury/
16 exp brain injury/
17 exp brain injury assessment/
18 ((head or crani* or cerebr* or capitis or brain* or forebrain* or skull* or hemispher* or intra-cran* or
intracran* or intra-cereb* or intracereb*) adj3 (infarct* or injur* or trauma* or damag* or wound* or fracture* or contusion*)).ab,ti,kw.
19 (Glasgow adj3 (coma or outcome) adj3 (scale* or score*)).ab,ti,kw.
20 diffuse axonal injur*.ti,ab,kw.
21 ((midbrain or mid brain) adj syndrome).ti,ab,kw.
22 (TBI or mTBI or sTBI).ti,ab,kw.
23 or/15-22
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24 muscle hypertonia/ or spastic paraplegia/ or spastic paresis/ or spasticity/
25 spasmolysis/
26 (spastic* or spasm*).ti,ab.
27 ((muscle* or muscular) adj3 (spasm* or cramp* or clonus or contractur* or hypertoni* or overact*)).ti,ab.
28 muscle contracture/ or muscle spasm/
29 or/24-28
30 14 and 23 and 29
31 remove duplicates from 30
Web of Science (WoS)
Indexes=SCI-EXPANDED, CPCI-S, ESCI Timespan=All years to 22-June-2017
Search 1. (TS=(“head injur*“ or ”head trauma“ or ”brain injur*“ or ”brain trauma“ or ”traumatic brain“ or TBI or mTBI or sTBI or
”traumatic head“ or ”cerebr* injur*“ or ”cerebr* trauma*“ or ”crani* injur*“ or ”crani* trauma*“) AND TS=(spastic*)) AND (TS=
(RCT or randomized or randomised or ”at random” or placebo) or TS=(random* same (allocat* or assign* or divi* or number)) OR
TI=(efficacy or effectiveness))
Search 2 (22-June-2017), citation search. References in WoS citing included studies identified to July 2016. WoS records were down-
loaded into EndNote and filtered for RCTs by searching for: ((RCT or randomised or randomized or randomly or placebo or double-blind)
[all fields] or trial[title field])
Clinical Trial Registers
ClinicalTrials.gov
Basic search 1: (spastic OR spasticity OR spasm OR spasms OR contracture OR contractures OR muscle hypertonia | Interventional
Studies | TBI OR sTBI OR mTBI or “brain injury” OR “brain injuries” OR “head injury” OR “head injuries” OR “traumatic brain”
OR “brain trauma”) OR Basic search 2: (Ipsen AND spasticity)
Trials for cerebral palsy or stroke patients (only) will be manually removed.
WHO International Clinical Trials Registry Platform (ICTRP)
Basic search: TBI AND spastic OR TBI AND spasticity OR TBI AND spasm OR TBI AND spasms OR TBI AND contracture OR
TBI AND contractures OR TBI ANDmuscle hypertonia OR mTBI AND spastic OR mTBI AND spasticity OR mTBI AND spasm
OR mTBI AND spasms OR mTBI AND contracture OR mTBI AND contractures OR mTBI AND muscle hypertonia OR sTBI
AND spastic OR sTBI AND spasticity OR sTBI AND spasm OR sTBI AND spasms OR sTBI AND contracture OR sTBI AND
contractures OR sTBI ANDmuscle hypertonia OR brain injury AND spastic OR brain injury AND spasticity OR brain injury AND
spasm OR brain injury AND spasms OR brain injury AND contracture OR brain injury AND contractures OR brain injury AND
muscle hypertonia OR
brain injuries AND spastic OR brain injuries AND spasticity OR brain injuries AND spasm OR brain injuries AND spasms OR brain
injuries AND contracture OR brain injuries AND contractures OR brain injuries AND muscle hypertonia OR head injury AND
spastic OR head injury AND spasticity OR head injury AND spasm OR head injury AND spasms OR head injury AND contracture
OR head injury AND contractures OR head injury AND muscle hypertonia OR head injuries AND spastic OR head injuries AND
spasticity OR head injuries AND spasm OR head injuries AND spasms OR head injuries AND contracture OR head injuries AND
contractures OR head injuries AND muscle hypertonia
C O N T R I B U T I O N S O F A U T H O R S
MC, KP and AS carried out study selection, data extraction and assessment of risk of bias.
OC, JW, KP, MC and AS completed analyses.
AS and KP led the writing of the manuscript, with input from MC and the coauthors.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol was published in 2010. Since that time the methodology of systematic reviews has evolved. To bring the protocol
and subsequent review in line with the latest Cochrane methodology wemade several necessary post-hoc adjustments to the assumptions
and processes. These were separately highlighted throughout the text.
During screening, we found a number of studies with clinically diverse populations. As people with TBI were poorly represented
(making up of only 26% of the participants), we therefore devised a threshold of 50% (meaning that the study needed to have at least
50% of participants with TBI to be included in the review) to ensure the evidence would be applicable to the TBI population. We
also made a post-hoc decision to use the Tardieu or Modified Tardieu Scale as our preferred measure of spasticity, in preference to the
Modified Ashworth Scale, in the instance that studies reported both these measures.
We added an information size calculation post-hoc, in line with updated Cochrane Injuries Group editorial policy, and ’Summary of
findings’ tables, in line with updated Cochrane standards.
Due to the paucity of data, a number of planned methods outlined in the protocol could not be implemented. These included the
plannedmeta-analysis, investigation of statistical heterogeneity, subgroup analysis, sensitivity analysis and assessment of reporting biases.
These methods will be retained for review updates pending sufficient studies.
The following authors joined the team since the publication of the protocol: AS, MC, OC, JW and LP.
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N O T E S
Since the publication of the protocol in 2010, network meta-analysis methods have been developed and adopted where necessary in
Cochrane Reviews. We recognise that the most appropriate design for our review (which aims to assess the effectiveness of a number
of interventions) would be that of a network meta-analysis.
However, in light of a number of issues identified while carrying out this review (such as the paucity of the data, number of available
interventions, presence of heterogeneity, lack of ’pure’ datasets for the condition of interest, etc.), we are aware that even if we were to
alter the design of this review, a network meta-analysis would not be feasible. The current state of the available literature also indicates
that in the short-term future updates of this review will encounter similar issues. We have hence retained the original protocol design
and have presented our findings as a narrative.
The network meta-analysis design remains a viable future plan should adequate data become available.
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